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GENERAL INTRODUCTION 
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1.1 Inflammageing: the centenarians lesson 
 
The extraordinary increase of the elderly in developed countries underscore the impor-
tance of studies on ageing and longevity and the need for the prompt spread of know-
ledge about ageing in order to satisfactorily decrease the medical, economic and social 
problems associated to advancing years for the increase of the subjects which are not 
autonomous and are affected by invalidating pathologies (Christensen K. et al. 2008). 
Ageing is a post-maturational process that, due to a diminished homeostasis and in-
creased organism vulnerability, causes a reduction of the response to environmental 
stimuli. 
The progressive decrease in physiological capacity and the reduced ability to respond to 
stresses lead to increased susceptibility and vulnerability to diseases. Thus, mortality 
due to all causes increases exponentially with ageing. 
This relentless process affects all cells, tissues, organs, and organisms, diminishing ho-
meostasis and increasing organism vulnerability (Franceschi et al., 2008). 
In particular,  ageing progression causes a reduction of the response to environmental 
stimuli and, in general, is associated with an increased predisposition to illness and 
death (Troen, 2003; Candore et al., 2006a). 
The main characteristic of aging is a chronic low-grade inflammation state clearly 
showed by 2–4-fold increase in serum levels of inflammatory mediators such as cyto-
kines and acute phase proteins in aged population, which act as predictors of mortality 
independent on pre-existing morbidity (Vasto et al. 2006). 
The group of Franceschi C.  conceptualized for the first time in 2000the term “Inflam-
mageing” a neologism, that indicates the tight relation between the role of inflamma-
tion and successful ageing. 
In particular, this term indicates the chronic low-grade inflammation typical of ageing, 
that seems to be the common biological factor responsible for the decline and the onset 
of disease in the elderly. 
The peculiar chronic inflammatory status which characterizes ageing, is under genetic 
control and is detrimental for longevity (Chung, H.Y et al. 2002; Zanni, F. et al. 2003). 
This age-related chronic inflammatory activity, leading to long term tissue damage, is 
related to mortality risk from all causes in old persons. A wide range of age-related dis-
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eases, such as neurodegeneration, atherosclerosis, diabetes, osteoporosis and sarcopenia, 
among others, share an inflammatory pathogenesis (Pawelec, G. et al.2002; Lio, D. et al 
2003; Roubenoff, R. 2003; Barbieri, M. et al. 2003;  Licastro, F. et al.2003;  Abbateco-
la, A.M et al. 2004; Roubenoff, R. et al. 2004). 
Inflammation is considered a response set by the tissues in response to injury elicited 
by trauma or infection. It is a complex network of molecular and cellular interactions 
that facilitates a return to physiological homeostasis and tissue repair. The individual re-
sponse against infection and trauma is also determined by gene variability. 
Actually, inflammation is defined, as a localized response with systemic consequences, 
elicited by injury or tissue damage, which helps to destroy, reduce or sequester both the 
harmful agent and the  wounded tissue. It is characterized in the acute form by the clas-
sical signs of pain, heat, redness, swelling and loss of function. In case the healthy tissue 
is not restored, or in response to stable low-grade irritation, inflammation becomes a 
chronic condition that continuously damages the surrounding tissues. In fact, chronic in-
flammation may have a rapid or slow onset but is characterized primarily by its persis-
tence and lack of clear resolution; it occurs when the tissues are unable to overcome the 
effects of the harmful agent. During chronic inflammatory events, immune responses, 
tissue injury and healing proceed simultaneously. The inflammatory response directs 
immune system components to the site of injury or infection. 
The inflammation is not per se a negative phenomenon: it is the response of the immune 
system to the aggression of viruses or bacteria. Nowadays the immune system must be 
active for more decades than in past centuries. This very long activity leads to a chronic 
inflammation that slowly but inexorably damages all the organs: this is a typical phe-
nomenon linked to aging considered the major risk factor for all the chronic age-related 
diseases (Licastro, F. et al. 2005) . 
Therefore, through inflammation and its mediators the IS influences not only the immu-
nological defense reactions, but also exerts detrimental effects on muscle, bone, cardiac 
function, hematopoiesis and cognition (Barbieri, M  et al.2003; Licastro, F. et al. 2003;  
Abbatecola, A.M. et al. 2004). Furthermore, the production of chemokines (RANTES, 
MIP-1a, IL-8, MCP-1) is also increased in the elderly, as a consequence of inflamma-
tion. Elevated IL6 serum levels are associated with diseases, disability and mortality in 
the elderly. 
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So, the ageing of immune system, definite as immunosenescence (IS), is the conse-
quence of the continuous attrition caused by chronic antigenic overload. Immunosenes-
cence and probably morbidity and mortality will be accelerated in those subjects who 
are exposed to an extra burden of antigenic load, such as chronic infections. 
Immunosenescence represents a complex remodelling, whereby some parameters de-
crease with age while others increase or remain unchanged (Franceschi, C., et al. 1998; 
Franceschi, C., et al. 2000; Franceschi, C., et al. 2000; Franceschi, C.,et al.1999). Re-
modelling suggests that not only a loss of function, but also complex changes in im-
mune function, occur with age. In particular, some functions appear to be up-regulated 
with aging; particularly important among these are the inflammatory response and the 
effector system of T lymphocytes. 
In particular, this  phenomenon is characterized by inflamm-ageing,  accumulation of 
memory and effector T cells, reduction of naive T cells, shrinkage of T cell repertoire, 
modification of CD4/CD8 T lymphocytes proportion, the involution of the thymus, re-
duction of the immunological space.  
The changes associated with immunosenescence are playing a more and more important 
role in the emergence of a series of age-related pathologies, conditioning the present ep-
idemiology of old people (Franceschi, C. 2003). Old people have to cope with a lifelong 
antigenic burden encompassing several decades of evolutionary unpredicted antigenic 
exposure. This chronic antigenic stress and the subsequent inflammatory burden have a 
major impact on survival and frailty. 
The quality of ageing and the peculiar remodeling of the IS in more advanced age are 
the results of the individual immunological history, which therefore heavily influences 
both longevity and successful ageing (Franceschi, C. and Bonafe`,M. 2003) . Individual 
immunological history derives from the interaction between genetic background and 
specific lifelong antigenic burden (Cooper, R.S. 2003;Hasty, P. et al. 2003). 
Inflammaging appears to be a universal phenomenon that accompanies the aging 
process, and which is related to frailty, morbidity and mortality in the elderly.  
However, very marked individual variability is observed: on the one hand, there are 
people who become frail and suffer early in life from age-related diseases that have an 
inflammatory pathogenesis; on the other, we observe healthy centenarians in whom 
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high levels of inflammatory mediators are present, thus suggesting  that inflammaging is 
compatible with very old age. 
Centenarians represent a cohort of select survivors who have, at least, markedly de-
layed diseases that normally cause mortality in the general population at earlier age. So, 
centenarians may be a human model of disease-free or at the least, disease delayed age-
ing (Franceschiet al., 1995; Franceschi and Bonafe, 2003). 
Centenarians are the best model in which to study human longevity. 
Thus centenarians have avoided or survived the most important pathologies that affect 
old people and are responsible for their morbidity and mortality. However, at the same 
time, centenarians are by definition extremely old people, and show all the signs and the 
characteristics of a prolonged aging process. 
In general, centenarian women outnumber centenarian men, and this is true all over the 
world. In Italy, a gradient exists from North to South, and the ratio between centenarian 
women and men decreases from about 7 : 1 in Northern Italy to 3 : 1 in Southern Italy  
(Passarino, G. et al. 2002). 
Centenarians as a model to study the determinants of aging and longevity in humans.  
Studies performed on centenarians compared to old subjects (usually about 60 years, 
when mortality goes up dramatically, in order to avoid cohort effects) have evidenced 
that centenarians escaped the major age-related diseases, and a minority of them is still 
in quite good health.  
As well known, life expectancy is a familial trait and  longevity is determined by differ-
ent factors. In particular, the environmental milieu and genetic background play a cen-
tral role.  
As demonstrated by many epidemiological studies, family members of long-lived sub-
ject shave a significant survival advantage compared to general population.  
In this context, the study of centenarian offspring (CO), a group of healthy elderly 
people with a familiar history of longevity, might help gerontologists to better identify 
the correlation between genetic profile and hope of a healthy ageing.  
Previous studies have reported that CO, like their centenarian parents, have genetic and 
immune system advantages, which reflect a minor risk to develop major age-related dis-
eases, such as cardiovascular diseases, hypertension or diabetes mellitus as well as can-
cer (Terry DF. et al. 2004a; Terry DF. et al. 2004b). 
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In these last years, some researchers have speculated about the distinctive immunologi-
cal profile of offspring enriched for longevity respect to the immunological features of 
coeval elderly. 
During ageing, B cell compartment shows significant modifications in numbers and 
functions (Colonna Romano G. et al 2003; Colonna Romano G. et al. 2002;  Listì F. et 
al. 2006; Candore G. et al. 1997).  
In fact, advanced age is per se a condition characterized by lack of B clonotypic im-
mune response to new extracellular pathogens. In any event, data are suggesting that the 
loss of naive B cells could represent a hallmark of immunosenescence (Colonna-
Romano G. et al. 2008). On the other hand, a B cell population lacking of both IgD and 
CD27 resulted increased in healthy elderly (Colonna-Romano G. et al. 2009).  
It is well documented that the quality and the size of the humoral immune response de-
clines with age (Bulati M. et al 2011; Frasca D. et al 2005; Dunn-Walters DK. et al. 
2010;  Cancro MP. et al 2009; Kumar R. and Burns E.A.  2008;Gibson KL. et al 2009; 
Grubeck-Loebenstein B. et al 2009).  
This change is characterized by lower antibody responses and decreased production of 
high affinity antibodies.  
The evaluation of IgM secreted in CO serum shows that the values are within the range 
of the levels observed in young subjects (Colonna-Romano G. et al 2010). 
 In this way, CO could have a bigger advantage to fight against new infections and ap-
propriately respond to vaccinations, giving them a selective advantage for longevity in 
healthiness. 
Whereby, individuals  genetically  enriched for longevity possess immune different sig-
natures respect to those of the general population . This suggests the idea of the “famili-
ar youth” of the immune system. 
Ageing in good condition seems directly correlated with a good functioning of the im-
mune system, suggesting that genes regulating the immune inflammatory responses are 
involved in longevity (Candore et al., 2006b; Franceschi et al., 2008). 
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1.2 Genetic determinants of successful or unsuccessful ageing. 
 
The idea that the longevity is based on genetic background is supported by many scien-
tific studies. 
Data obtained in a study of Scandinavian twins suggest that lifespan is influenced by 
genetics for 25% (Ljungquist B. et al. 1998).  
But these studies have not been carried out on nonagenarians and centenarians, so they 
do not have information about the maximum lifespan. However, centenarian siblings 
have an increased probability of a prolonged existence and the age at death of the cente-
narian parents is higher than the expectancy of their birth cohort. It is perhaps unsurpris-
ing that parents and siblings of centenarians are themselves relatively long-lived. Given 
the rarity of life-long mortality differences between social groups defined in other ways, 
these findings suggest a substantial familial component in differentiating exceptionally 
long-lived individuals from the rest of the population.  
Obviously, as previously stated, a familiar trait could be environmental, behavioral, or 
genetic.  
In the present study we focus on the role of the genes that control immune-
inflammatory responses. 
According to evolutionary ageing theories, most of the parameters influencing immuno-
senescence appear to be under genetic control (Capri M. et al. 2008; Troen BR. 2003; 
Ostan R. et al 2008).  
An example is given by the innate immune system, involved in neutralizing infectious 
agents (Candore G. et al.2006). It plays a beneficial role until the time of reproduction 
and parental care. In old age, a period largely not foreseen by evolution, it can deter-
mine an opposite and detrimental effect through chronic inflammatory responses (“an-
tagonistic pleiotropy”) (Ostan R. et al 2008; Williams GC. 1957). 
Genetic pro-/anti-inflammatory variations in innate immune response are, indeed, 
thought to influence the susceptibility of age-related human diseases, by altering ost re-
sponse to environmental and endogenous stress (Vasto S. et al. 2007). Thus, they are 
able to determine a negative or positive control of inflammation, by affecting both inte-
ractions between host and microbes and survival of the individual and attainment of 
longevity. Furthermore, they appear both to be responsible, at least in large part, for dif-
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ferent men and women strategies to achieve longevity, and to contribute to the preferen-
tial sex dimorphism of the age-related diseases (Candore G. et al.2010; Candore G. et 
al.2006; Lio D. et al. 2002). 
Indeed, the genes involved in the inflammation process are numerous, as well as the 
genomic variations within most of these genes. 
The role of an individual genetic background and predisposition for the extent of an in-
flammatory response is determined by variability of genes encoding endogenous media-
tors that constitute the pathways of inflammation.  
The genetically determined capacity of mediator production and release might contri-
bute to a wide range of clinical manifestations of an inflammatory disease (Feghali and 
Wright, 1997; Imahara and O’Keefe, 2004; Hollegaard and Bidwell, 2006; Licastro et 
al., 2005). 
The individual genetic background and the eventual influence of counteracting cyto-
kines could therefore play a determinating role in the onset of age-related diseases. 
Genetic variations located within the promoter regions of pro-inflammatory and regula-
tory cytokines could influence inflamm-ageing and the susceptibility to age-related dis-
eases (Lio D. et al. 2003). 
Centenarians show a complex and peculiar balancing between pro-inflammatory and 
anti-inflammatory characteristics, either phenotypically or genetically (Franceschi C. et 
al. 2007) whose net result is a slower, more limited and balanced development of in-
flamm-ageing in comparison to other old people, who are characterized by either faster 
or inadequately counteracted anti-inflammatory responses (Franceschi C. and Bonafè 
M. 2003). 
A potentially important consequence of the age related impairment of the balancing be-
tween inflammatory and anti-inflammatory agents is a profound, systemic modification 
of cellular microenvironment(s), which in turn can determine a different rate of ageing 
of organs and tissues, leading to the so-called ‘mosaic of ageing’ (Cevenini E. et al. 
2008).  
Furthermore, the age-related and inflammation-related change of cell microenvironment 
can also cause a remodelling in epigenetic and gene expression at different ages. 
Within this perspective, healthy aging and longevity are likely the result not only of a 
lower propensity to mount inflammatory responses but also of efficient anti-
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inflammatory networks, which in normal aging fail to fully neutralize the inflammatory 
processes consequent to the lifelong antigenic burden and exposure to damaging agents.  
Such a global imbalance can be a major driving force for frailty and common age-
related pathologies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The balancing between pro- and anti-inflammatory agents. Efficient inflammatory responses can 
confer high resistance to infectious diseases, but also an increased susceptibility to inflammation-based 
diseases later in life. On the other side, low inflammatory responses, while rendering more susceptible to 
infectious diseases, can confer a survival advantage in old age. PG: prostaglandins; LT: leukotrienes, 
LPX: lipoxins. Squares indicate factors whose contribution to longevity have not been studied yet. 
 
 
 
These studies support the existence of buffering mechanisms operating in the determi-
nation of human longevity, probably through the presence of favorable genotypes con-
trasting the deleterious effect of age-related disease genes: as a result, the frequency of 
deleterious genotypes may increase among individuals with extreme lifespan because 
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their protective genotype allows disease-related genes to accumulate (Bergman A. et al. 
2007). 
A better understanding of the functional genes that affect healthy longevity in humans 
may lead to a rational basis for intervention strategies that can delay or prevent age-
related diseases. 
Genetic variations (gene polymorphisms) located within the promoter regions of pro-
inflammatory cytokines have been shown to influence the susceptibility to age-related 
diseases, by increasing gene transcription and therefore cytokine production. Converse-
ly, genetic variations determining increased production of anti-inflammatory cytokines 
or decreased production of pro-inflammatory cytokines have been shown to be asso-
ciated with successful ageing, suggesting a role for the control of the inflammatory state 
in the attainment of healthy longevity (Lio et al., 2003; Carrieri et al., 2004).  
So, it is emergent evidence that polymorphic alleles of inflammatory cytokines, in-
volved in high cytokine production, are related to unsuccessful aging as atherosclerosis 
and Alzheimer’s disease; reciprocally, controlling inflammatory status may allow to us 
better attain successful aging (Candore G. et al. 2006). 
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1.3 Cytokine profile: a biomarker for successful ageing 
 
Cytokines are considered key players in maintaining lymphocyte homeostasis (Sanjabi 
S. et al.2009; Iannitti T and  Palmieri B 2011). Their function is not limited to induce 
response after an immune insult, but they can modulate the nature of response (cytotox-
ic, humoral, cell mediated, inflammatory or allergic) or, in contrast, they may cause 
non-responsiveness and active immunesuppression (Iannitti T and  Palmieri B 2011).  
Cytokines interact in networks in which the functions of one cytokine are modified, 
modulated or substituted by another one. 
For example, IL-10 and TNF-α have complex and predominantly opposing roles in the 
inflammatory responses (Hajeer and Hutchinson, 2001; Girndt et al., 2002). IL-10 limits 
and ultimately terminates inflammatory responses, whereas TNF-α determines strength, 
effectiveness and duration of inflammatory reactions.  
TNF-α is an independent prognostic marker for mortality in persons aged 100 years 
(Bruunsgaard et al., 2003b). 
Furthermore, sequence variations in several cytokine genes, such as IFN-γ and IL-10 
genes, have been demonstrated to be associated with successful ageing and longevity 
(Iannitti T. and Palmieri B 2011). 
On the other hand, individual changes in type and intensity of immune response affect-
ing life span expectancy and health ageing seem to have a genetic component. A well-
preserved immune function characterizing the successful ageing has been found in cen-
tenarians (Ostan R. et al.2008). 
Recent evidence suggests that centenarians seem to be genetically equipped gene poly-
morphism for overcame the major age-related diseases and polymorphisms in immune 
system genes involved in regulation of immune responses have been found associated to 
longevity. 
In particular, associations between both cytokine gene polymorphisms and longevity, 
and differential  gender longevity in males and females, and reciprocally to age-related 
diseases have been demonstrated (Ostan R. et al. 2008; Iannitti T. and Palmieri B 2011; 
Caruso C. et al. 2005 ). 
Interpersonal differences in the regulation of cytokines  production, as IL10 and TNFα, 
may be critical with respect to the final outcome of an inflammatory response.  
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The increased production of IL-6 and TNF-α and the reduced production of growth 
hormone and IGF-I are directly involved in the loss of fat-free mass during ageing. 
Low-grade elevations in levels of circulating pro inflammatory cytokines and their re-
ceptors, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, interleukin 
(IL)-1 receptor antagonist (IL-1Ra), soluble TNF receptors, etc., are strong independent 
risk factors of morbidity and mortality in the elderly (Bruunsgaard and Pedersen, 2003; 
Bruunsgaard et al.,2003a). A further consequence of hyper production of pro inflamma-
tory cytokines in the elderly is the increased production of diverse chemokines 
(RANTES, MIP-1α, IL-8, MCP-1) (Appay and Rowland-Jones, 2002; Tracy, 2003) and 
the increase in C reactive protein (CRP) levels (Di Iorio et al.,2003; Mariani et al., 
2002; Bo et al., 2005). 
Frailty and disability in the elderly represent the complex and cumulative expression of 
the altered production of such inflammatory cytokines (Di Iorio et al., 2003; Sandmand 
etal., 2003). In support of this hypothesis, increased levels of inflammatory serum 
markers in the elderly are associated with dementia, Parkinson's disease, atherosclerosis, 
type 2 diabetes, sarcopenia, functional disability and high mortality risk (Franceschi et 
al., 2001; Abbatecola et al., 2004; Barbieri etal., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Inflamm-ageing, cytokine network and age-related diseases. Cytokines mainly involved in the 
pathogenesis and progression of specific disease entities are sho 
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Furthermore, it seem that those individuals who are genetically predisposed to produce 
low levels of inflammatory cytokines or high levels of anti-inflammatory cytokines 
have an increased capacity to reach the extreme limits of the human life-span. (Pawelec 
et al. 2002, Candore et  al. 2003, Lio et al. 2003). 
In particular,  a considerable body of data indicates that particular cytokine polymor-
phisms, especially those involving IL-6, TNF-α, and IL-10 genes, may influence sus-
ceptibility, and in some cases prognosis in age-related disease. 
In this regard,  a study performed on Italian centenarians reported that those individuals 
who are genetically predisposed to produce high levels of IL-6 during aging, homozyg-
ous for the IL-6 −174GG,  that is, C-negative men at IL-6 –174 C/G single nucleotide 
polymorphism (SNP) have a reduced capacity to reach the extreme limits of human li-
fespan (Bonafè , M.  et al. 2001). 
Independent studies found that high IL-6 levels are the major predictor of disability and 
mortality in the elderly.  
Further studies have shown that the IL-6 −174GG genotype is underrepresented in cen-
tenarians, thus to be consider that the IL-6−174 genotype may be a major  modulator of  
inflammaging. 
In particular it was shown that this phenomenon to be restricted primarily to males, sug-
gesting that the two genders follow different trajectories to attain longevity. 
Several data suggest that IL-6 −174 C/G locus variability is capable of modulating the 
individual susceptibility to common causes of morbidity and mortality among elderly, 
such as type 2 diabetes, cardiovascular diseases, Alzheimer’sdisease and dementia, 
among others, thus influencing individual life span (Licastro et al., 2003; Olivieri et al., 
2003; Franceschiet al., 2005).  
Similar data on the decreased frequency of IL-6 −174 C-carriers in Irish octogenarian 
subjects from the BELFAST elderly longitudinal ageing study have been reported (Rea 
et al., 2003; Ross et al., 2003).  
Some of recent evidence has, in fact, linked cytokine polymorphisms with longevity and 
differential longevity between males and females in the Italian population.  
Moreover, other  data indicate that –1082G IL-10 SNP, associated with a high produc-
tion of the cytokine, is increased among Italian male centenarians (Lio D. et al.2004; 
Lio, D. et al. 2002; Lio D. et al.2003). 
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In a study on 190 Italian centenarians, the IL-10 −1082G/G polymorphism has been 
demonstrated to be a specific marker for longevity (Lio et al.,2002). This genotype, as-
sociated with high IL-10 production, was argued to confer an anti-inflammatory status, 
thus enhancing the possibility to attain extreme longevity.  
IL-10 gene codifies for IL-10 cytokine. IL-10 is produced by macrophages, T and B 
cells. It is one of the major immune-regulatory cytokines, usually considered to mediate 
potent down-regulation of inflammatory responses. IL-10 production, independently on 
interaction with other cytokine gene products, is generally controlled by several poly-
morphic elements in the 5’flanking region of IL-10 gene. Multiple SNPs have been 
identified in human IL-10 5’flanking region and some of these (i.e. -592, -819, -1082) 
combine with microsatellite alleles to form haplotype associated with differential IL-10 
production. 
These three SNPs in the IL-10 proximal gene region (considered potential targets for 
transcription regulating factors) might be involved in genetic control of IL-10 produc-
tion. 
In particular, the homozygous -1082GG genotype seems to be associated with higher 
IL-10 production respect to G/A heterozygous and AA homozygous genotypes. 
An interferon γ polymorphism was found to be a likely marker for inflammaging in 
women (Lio D. et al. 2002). 
It is interesting to note that the IL-10 −1082 GC genotype, that likely confers an advan-
tage to become a centenarian, is much less frequent in patients affected by Alzheimer's 
disease. 
IFN-γ gene codifies for a cytokine involved in defense against viruses and intracellular 
pathogens, and in induction of immune mediated inflammatory responses. 
Its production is genetically regulated. A variable length CA repeat sequence in the first 
intron of IFN-γ gene has been described to be associated with high IFN-γ production. 
Furthermore, a SNP, T to A (+874 T/A), at 59 end of the CA repeat region has been de-
scribed and T presence has been related to high-producing microsatellite allele 2. This 
SNP coincides with a putative NF-_B binding site, which might have functional conse-
quences for transcription of IFN−γ gene. Thus, this SNP might directly influence IFN-g 
production levels associated to CA microsatellite marker (Lio D. et al. 2002) . 
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In centenarians, our group first reported that possession of the +874A allele conferred 
an overall anti-inflammatory status promoting longevity, particularly in centenarian fe-
males (Lio et al. 2002a). 
Alongside our recent findings allow us to suggest that different alleles at different genes 
coding for pro- or anti-inflammatory molecules may affect individual life-span expec-
tancy by influencing the type and intensity of the immune-inflammatory responses 
against environmental stressors (Caruso et al., 2005; Franceschi et al., 2005; Rea et al., 
2006). 
Moreover, centenarian offspring have a marked increased likelihood of surviving up to 
100 years and show a reduced prevalence of age-associated diseases, in particular re-
lated to cardiovascular diseases and less prevalence of cardiovascular risk factors (Terry 
et al., 2003). So, genes involved in CVD, the leading worldwide cause of morbidity and 
death (Nabel, 2003), should play an opposite role in human longevity. 
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1.4. Metabolic Syndrome (MetS),  Cardiovascular diseases and Cancer 
 
The metabolic syndrome (MetS) is defined by a constellation of interconnected phy-
siological, biochemical, clinical, and metabolic factors that directly increases the risk of 
cardiovascular disease, type 2 diabetes mellitus, and all cause mortality.  
Insulin resistance, visceral adiposity, atherogenic  dyslipidemia, endothelial dysfunc-
tion, genetic susceptibility, elevated blood pressure, hyper coagulable state, and chronic 
stress are the several factors which constitute the syndrome.  
Chronic inflammation is known to be associated with visceral obesity and insulin resis-
tance which is characterized by production of abnormal adipocytokines such as tumor 
necrosis factor (TNFα), interleukin-1 (IL-1), IL-6, leptin, and adiponectin.  
The interaction between components of the clinical phenotype of the syndrome with its 
biological phenotype (insulin resistance, dyslipidemia, etc.) contributes to the develop-
ment of a pro inflammatory state and further a chronic, subclinical vascular inflamma-
tion which modulates and results in atherosclerotic processes. 
The metabolic syndrome confers a 5-fold increase in the risk of type 2 diabetes mellitus 
(T2DM) and 2-fold the risk of developing cardiovascular disease (CVD) over the next 5 
to 10 years (Alberti K. G. M. M.  et al. 2009). 
Further, patients with the MetS are at 2- to 4-fold increased risk of stroke, a 3- to 4-
foldincreased risk of myocardial infarction (MI), and 2-foldthe risk of dying from such 
an event compared with those without the syndrome (Alberti K. G.M.M. and Zimmet P. 
2005)  regardless of a previous history of cardiovascular events (Olijhoek, J. K. et al. 
2004). 
It further increases with age (10% in individuals aged 20–29, 20% in individuals aged 
40–49, and 45% in individuals aged 60–69) (Ford E.S. et al.2002). 
The prevalence of MetS (based on NCEP-ATP III criteria, 2001) varied from 8% to 
43%in men and from 7% to 56% in women around the world (Cameron J.E. et al. 
2004).  
Park Y.W. et al. (2003) noticed that there is an increase in the prevalence of MetS from 
20 years old through the sixth and seventh decade of life for males and females, respec-
tively. 
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MetS is a state of chronic low grade inflammation as a consequence of complex inter-
play between genetic and environmental factors.  
Insulin resistance and inflammation are postulated among the important underlying pa-
thophysiologies of the syndrome (Reaven GM. 1988).  
Increased levels of inflammation markers such as C-reactive protein (CRP) and inter-
leukin-6 (IL-6) are observed in subjects with MetS (Dandona P. et al. 2004; Ridker PM. 
et al.2003; Wannamethee SG. et al. 2005) as well as in people with components of 
MetS (Frohlich M. et al.2000; Lakoski SG. et al 2005;Piche ME. et al 2005; Sesso HD. 
et al 2007). 
Insulin Resistance is defined as a pathophysiological condition in which a normal insu-
lin concentration does not adequately produce a normal insulin response in the peripher-
al target tissues such as adipose, muscle, and liver. Under this condition, pancreatic beta 
cell secretes more insulin (i.e., hyperinsulinemia) to overcome the hyperglycemia 
among insulin-resistant individuals. 
Although hyperinsulinemia may compensate for insulin resistance to some biological 
actions of insulin, that is, maintenance of normoglycemia, however, it may cause an 
over expression of insulin activity in some normally sensitive tissues. This accentuation 
of some insulin actions coupled with a resistance to other actions of insulin results in the 
clinical manifestations of MetS (Gill H. et al 2005). 
The great variations in the susceptibility and age of onset in individuals with a very sim-
ilar risk profile suggest a major interaction between genetic and environmental factors 
(Ordovas J.M. et al 2007). It is recognized that some people who are not obese by tradi-
tional measures nevertheless are insulin resistant and have abnormal levels of metabolic 
risk factors. 
Examples are seen in individuals with 2 diabetic parents or 1parent and a first- or 
second-degree relative (Perseghin G. 1997). 
It is likely that the expression of each metabolic risk factor falls partially under its own 
genetic control, which influences the response to different environmental exposures. For 
example, a variety of polymorphisms in genes affecting lipoprotein metabolism are as-
sociated with the worsening of dyslipidemia among obese people (Laakso M. 2004). 
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Similarly, a genetic predisposition to the defective insulin secretion when combined 
with insulin resistance can raise the plasma glucose to abnormal levels (Poulsen P. et al 
2005). 
The metabolic syndrome is a constellation of risk factors that co-segregateand is asso-
ciated with increased cardiovascular events (McNeill AM et al 2006; Wilson PW et al 
2005). 
It is shown that inflammation markers and metabolic syndrome are associated with risk 
of congestive heart failure (CHF).  
Suzuki T. et al.( 2008) studied 4017 men and women > or =65 years old, without base-
line CHF or diabetes, participating in the Cardiovascular Health Study, an observational 
study with 12.2 years follow-up and 966 cases of incident CHF. They  observed that in-
flammation markers provided additive information on CHF risk in this elderly cohort. 
So, inflammation markers and MetS together may be useful in clinical and research set-
tings. 
Several studies have shown that centenarians have better cardiovascular risk profiles 
compared to younger old people. Some reports have revealed that cardiovascular dis-
eases (i.e. hypertension, diabetes, angina and/or myocardial infarction) are less common 
in centenarians respect to 70 and 80 years old persons. 
Among older population, centenarians may be considered the best example of success-
ful cardiovascular aging. 
The capacity to avoid, delay or limit cardiovascular damage associated with aging-
related diseases has been proposed as one of the mechanisms that may help to explain 
the successful aging in centenarians. In particular, lower incidence of cardiovascular 
diseases has been observed in centenarians, which represent the most frequent causes of 
death at younger ages (70–80 years). 
The examination of death certificates  has shown a decreased frequency of diabetes and 
myocardial infarction as causes of death in centenarians in contrast with the accepted 
concept that atherosclerosis and congestive heart failure increase in frequency with age 
(Gessert et al., 2002). These findings suggest that centenarians appear to ‘‘outlive’’the 
cardiovascular risk factors for many of the conditions that are frequent causes of death 
at the age of 70, 80, or 90 years. 
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The advantages of a favorable cardiovascular risk profile in centenarians seem to be 
transmitted to their descendants, who exhibit better cardiovascular risk profiles com-
pared to age-matched people without centenarian relatives (Perls and Terry, 2003). This 
supports the existence of  genetic determinants in the genesis of arteriosclerosis and its 
complications. In addition, a more favorable inflammatory atherogenic profile has been 
reported in centenarians together with a better antioxidant profile (Fletcher et al.,2003), 
which is in accordance with the inflammatory and oxidative stress hypothesis of cardi-
ovascular aging (Chunget al., 2001). 
Together with a favorable genetic profile, a key aspect that seems to be present in most 
of those who have reachedan exceptional old age is to have conducted a healthy lifestyle 
(Perls and Terry, 2003). 
The incidence of atherosclerosis is markedly linked to the presence of a pro-
inflammatory status (Viles-Gonzalezet al., 2006). Thus, control of inflammatory reac-
tions may also decrease the incidence of cardiovascular diseases. 
The predictive validity of traditional cardiovascular risk factors diminishes with increas-
ing age (Cesari et al., 2004; Casiglia and Palatini, 1998).  
Various reports have indicated that inflammatory markers appear to be predictive of 
cardiovascular events, especially in aged populations (Harris et al., 1999; Volpato et al., 
2001; Bruunsgaard et al., 2000; Vasan et al., 2003; Ridker et al., 2000).  
CRP is increasingly measured to stratify coronary artery disease risk and guide clinical 
management (Ridker, 1998; Bogaty et al., 2005). Simultaneous assessment of markers 
of inflammation and lipid metabolism may improve cardiovascular risk stratification in 
patients with stable coronary artery disease (Hoffmeister et al., 2005). 
Gene polymorphisms for pro-inflammatory cytokines seem to contribute significantly to 
the risk of atherosclerosis related diseases (Candore et al., 2006a; Lio et al., 2004). 
The linkage between inflammation, genetic factors and atherosclerosis has been demon-
strated by the analysis of the frequency of pro-inflammatory and anti-inflammatory ge-
notypes in Italian centenarians. In this population, the frequency of the genotype asso-
ciated with interleukin 10 (-1082GG) is related to a significant increased production of 
this anti-inflammatory cytokine. Conversely, the frequency of the genotype associated 
with low production of  IL 10 is significantly higher in patients with acute myocardial 
infarction compared to controls. 
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Although a low production of interleukin 10 is associated with an increased resistance 
to pathogens, increased concentrations of this cytokine seems to be linked to a better 
control of inflammatory responses induced by chronic vessel damage, and with a re-
duced risk for atherogenic complications (Lio et al., 2004). 
A 7-year prospective cohort study assessed the incidence of coronary heart disease, 
stroke and congestive heart failure events according to serum levels of CRP, IL-6 and 
TNF-α in a large sample of older, well-functioning subjects (Cesari et al.,2003).  
It has been shown that IL-6 is significantly associated with all outcomes, whereas TNF-
αshowed significant associations with coronary heart disease and CRP was associated 
with congestive heart failure events. Also, IL-1β serum levels are associated with con-
gestive heart failure and angina, supporting the hypothesis that IL-1β is mainly involved 
in the functional alterations of cardiomyocytes (Di Iorio et al., 2003). 
It has been suggested that different genotypes of inflammatory molecules (pro- and anti-
inflammatory cytokines) may have opposite effects on predisposing to atherosclerosis 
and accelerated vascular aging or longevity (Candore et al., 2006a). 
In addition to cardiovascular disease, individual components of the metabolic syndrome 
have been linked to the development of cancer, particularly to colorectal cancer (Kreger 
BE et al. 1991) . 
Colorectal cancer is an important health problem since one million new cases are diag-
nosed world-wide each year with half million related deaths  (Boyle P and Leon ME 
2002). 
This association is sustained by many epidemiological studies. Recent reports suggest 
that individuals with metabolic syndrome have a higher risk of colon or rectal cancer. 
Moreover, the clusters of metabolic syndrome components increase the risk of asso-
ciated cancer. 
Accumulating evidence suggests that systemic inflammation might be a mechanism that 
play a major role in colon carcinogenesis. 
Studies have shown that genetic variations in inflammation-related genes, such as inter-
leukin (IL)-6, IL-8, and IL-10, are associated with susceptibility to colorectal cancer and 
adenomas. 
IL-6 appears to enhance tumorigenesis by a paracrine and autocrine mechanism, to sti-
mulate cell growth and inhibit apoptosis. Also IL-6 concentrations reflected disease sta-
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tus and were commonly associated with metastatic disease (Chung YC and Chang YF 
2003). 
There are several studies which demonstrated the correlation between high levels of IL-
6, TNF-α, C-reactive proteins (CRP) and colorectal carcinogenesis.  
Moreover, a Greek study demonstrated that high levels of serum IL-6, TNF-α and CRP 
were correlated with larger tumor size.  
The relation to tumor size could be related to the fact, that larger tumors may trigger a 
more potent immunological response manifested by the circulation of proinflammatory 
cytokines such as TNF-α (Nikiteas NI et al. 2005). 
Understanding the pathological mechanism that links metabolic syndrome and its com-
ponents to carcinogenesis has a major clinical significance and may have profound 
health benefits on a number of diseases including cancer, which represents a major 
cause of mortality and morbidity in our societies. 
In this sense, we also need to take inconsideration the role of immunological balance 
Th1/Th2 on a genetically predisposed  perspective, so that several functional single nuc-
leotide polymorphisms (SNP) located in critical transcription positions may affect the 
high and low production of inflammation mediators, and these molecular differences are 
all together responsible of individual difference in exacerbation or fast resolution of in-
flammatory events (Lio et al. 2003, Forte et al. 2006). 
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1.5 Aims of the study and outline of this thesis 
 
Aging is a post-maturational process that, because of a diminished homeostasis and in-
creased organism vulnerability, causes a reduction of the response to environmental 
stimuli. The progressive decrease in physiological capacity and the reduced ability to 
respond to stresses lead to increased susceptibility and vulnerability to disease. Thus, 
mortality due to all causes increases exponentially with aging.  
Aging involves all the cells, tissues, organs, and organisms and is modulated by external 
factors. 
Ageing is accompanied by chronic low-grade inflammation state clearly showed by 2–
4-fold increase in serum levels of inflammatory mediators such as cytokines and acute 
phase proteins in aged population, which act as predictors of mortality independent on 
pre-existing morbidity. 
More interestingly, studies of gene expression have demonstrated that in the aged sever-
al genes show an increase or a decrease in expression. Usually the genes over expressed 
are active in stress conditions, such as inflammation (Weindruch, R. et al. 2002; Troen, 
B.R. 2003; Wick, G. et al. 2003; Franceschi, C. et al. 2000). 
Thus inflammaging is a mechanism of aging per se, and this could constitute the com-
mon driving force of most age-related pathologies.such as atherosclerosis, cardiovascu-
lar diseases, type 2 diabetes, metabolic syndrome, sarcopenia, osteoporosis, cognitive 
decline and frailty (De Martinis M. et al. 2005; Bucci L. et al 2009). 
Centenarians are equipped to reach the extreme limits of human life span and, most im-
portantly, to show relatively good health, being able to perform their routine daily life 
and to escape fatal age-related diseases. Thus, they are the best example of extreme lon-
gevity, representing selected people in which the appearance of major age-related dis-
eases, such as cancer, and cardiovascular diseases among others, has been consistently 
delayed or escaped. 
In this scenario, multiple cytokines play a critical role in orchestrating and perpetuating 
inflammation in age-related disease pathogenesis and several specific cytokines and 
chemokines inhibitors are now in development as future therapy for these diseases 
(Barnes et al. 2003). 
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Tight relation between successful ageing and inflammation is, nowadays, largely 
claimed in literature and confirmed by the recognized inflammatory pathogenesis of 
main age-related diseases as Atherosclerosis, Alzheimer Disease, cardiovascular diseas-
es, cancer etc.  
Therefore, improvement in acknowledgments of individual genetic contribute and mo-
lecular mechanisms occurring in inflammatory response are essential in future therapeu-
tic approach to favorite successful ageing. 
Aim of the researches reported in this thesis was  to contribute on the understanding ge-
netic predisposing background role in onset of some age-related disease, in particular, 
cardiovascular diseases, as Acute Ischemic Stroke, Thoracic Aortic Aneurysm, Takot-
subo Cardiomyopathy, Myocardial infarction and Sporadic Colon Cancer thath have a 
common soil in methabolic syndrome in the light of data acquired on genetic of lon-
gevity of Sicilian centenarians and  of nonagenarians as a model of successful ageing. 
Here are reported data from  association studies that have produced informative results 
on inflamm-ageing obtained studying  age-advanced population, centenarians and pa-
tients affected of different cardiovascular diseases. 
In particular, Chapter 2 is devoted  to a collection of our data gathered for over 10 
years in Sicilian centenarians and recently summarized in a review (Balistreri C.R. et al. 
2012). Our group examined the role of their genetic background and immune system on 
longevity. We have discussed the role of an over-expression of anti-inflammatory se-
quence variants of immune/inflammatory genes in longevity.  We investigated in Sici-
lian population, SNPs or genetic variants of TLR4, CCR5, Cox2, 5-Lo genes observing 
the association of gender and longevity. Furthermore,  we analyzed allelic and genotyp-
ic frequencies of  such polymorphisms located on IFN-g and IL10 genes. 
In Chapter 3 are reported data from an our study that suggested the possibility to use 
cytokine profile as biomarker of successful ageing, by evaluating through Luminex 
technology cytokine serum levels in  Sicilian nonagenarians and  control subjects (aged 
between 30 and 50 years old) (Palmeri M. et al. 2012). 
In particular, we analyzed a panel of 17 cytokines, comprehensive of haematopoietic 
factors T helper 1 (Th1), Th2, inflammation regulatory cytokines, and chemokines, as: 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17, IFN-γ, TNF-
α, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1b 
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(MIP-1b), granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulo-
cyte colony-stimulating factor (G-CSF). 
In Chapter 4  are reported data from an our study investigating the role of some cyto-
kine polymorphisms, conditioning individual inflammatory response in a typical cardi-
ovascular event:  the acute ischemic stroke (Tuttolomondo A. et al 2012). 
In particular, in patients affected by acute ischemic stroke, we evaluated the role of 
SNPs of some pro-inflammatory/anti-inflammatory and coagulation/fibrinolytic genes. 
We analyzed a functional TNF-α  polymorphism (-308G/A), -1082/819 haplotypes of 
IL-10 gene, IL-1RN exon 2 VNR polymorphism, alleles at the 174 nucleotide (174G/C) 
of IL-6 gene, PAI-1675 5G/4G polymorphism and alleles at the 7351 nucleotide 
(7351C/T) of tPA gene was undertaken in the patient groups and in the control subjects. 
To understand better the genetic basis of complex diseases like ischemic stroke and to 
delineate a possible stroke risk profile in subjects with cerebrovascular risk factors. 
Chapter 5, is dedicated to the examination of the role of the genetic background in sus-
ceptibility to acute myocardial infarction (AMI) in young men (Vaccarino L. et al. 
2013). 
In this study, we analyzed the frequencies of polymorphisms 20210G/A of FII and 
308G/A of the promoter region of TNF-α in a group of Sicilian patients aged <46 years 
affected by AMI and evaluated the effect of these polymorphisms on the blood levels of 
myocardial tissue damage and clotting markers, to evaluate the possibility to use typing 
of these polymorphisms in association with selected haematochemical parameters in 
prognostic evaluation of these patients. 
Young adults are a relatively small proportion of patients who experience AMI. They 
have some distinct characteristics compared to older patients as young people are more 
likely to have normal coronary arteries; so they are an example of unsuccessful aging.  
In our previous reports, we have observed a significant distribution of pro/anti-
inflammatory genes among male controls, male centenarians and male patients affected 
by acute myocardial infarction (AMI).  
The frequencies of the studied pro inflammatory alleles were significantly lower in cen-
tenarians and higher in AMI patients, i.e. the number of centenarians with a pro-
inflammatory allele was lower than the number of AMI patients with the polymorphism. 
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Conversely the frequencies of anti-inflammatory alleles were significantly lower in 
AMI patients and higher in oldest old, in both cases age-related  controls presented in-
termediate frequency values (Balistreri et al., 2004; Caruso et al., 2004;Lio et al., 2004; 
Listı` et al., 2005; Listı` et al., 2006a,b; Candoreet al., 2006d; Grimaldi et al., 2006). 
These results strengthen the hypothesis that genetic background protecting against car-
diovascular disease is a relevant component of the longevity  trait at least in men where 
these studies have been performed (Candore et al., 2006a,d; Caruso et al., 2005), thus in 
successful ageing: genetic background of male centenarians is protective against coro-
nary heart disease. 
Furthermore, In Chapters 6  and 7 it was described another cardiovascular disease that 
characterizes aging: the Thoracic aortic aneurysm (TAA), a progressive disorder involv-
ing gradual dilation of ascending and/or descending thoracic aorta with dissection or 
rupture as complications. 
In particular, in Chapter 6 it were researched phenotypes associated with the risk of 
aorta rupture and dissection in aged S-TAA individuals (Balistreri C.R. et al. 2014).  
Thus, in this study,  were assessed histopathological and immunohistochemical analyses 
in aorta specimens from 100 S-TAA patients with median age of 62.95 –  11.44 years 
and age and gender-matched controls.  
Our major goal was to identify a biomarker of rupture and/or dissection in aged individ-
uals that is useful both for applying different surgical approaches and providing appro-
priate surgical indications. 
 In Chapter 7 it was evaluated the role of functional variants located in some cytokine 
genes to understand better the sporadic TAA susceptibility factors and prevention (Vac-
carino L. et al. 2014). 
Our interest has been focused on investigating the role of genetic variants of transform-
ing growth factor-β (TGF-β) pathways in TAA risk. 
We analyzed allelic and genotypic frequencies of these polymorphisms located on en-
coding TGF-β isoforms and receptors genes, as:  rs1800471 TGF-β1 cod25;  rs900 TGF-
β2 3’UTR; rs334348 TGF-βR1 3’UTR; rs334349 TGF-βR1 3’UTR and  rs4522809 
TGF-βR2 Intron +3919. 
In addition, other cytokines, including IL-10,an anti-inflammatory cytokine able to 
modulate activity of TGF-β pathways. orchestrate TAA pathophysiology. Thus, we ana-
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lyzed  also, the role of some common single nucleotide polymorphisms (SNPs) of genes 
encoding IL-10 and receptor in sporadic TAA, as:  rs1800896 IL-10 (−1082 G>A); 
rs1800871 IL-10 ( −819 C>T); rs1800872  IL-10 ( −592 C>A); rs3024496 IL10  (Not 
defined C>T) and rs283467 IL-10RB (Codon 47 A>G). 
Their balance determines the ultimate fate of the aortic wall as healing atherosclerosis 
or aneurysm formation. 
Chapter 8 is dedicated to  Takotsubo cardiomyopathy (TTC) is an increasingly re-
ported clinical syndrome that mimics acute myocardial infarction without obstructive 
coronary artery disease and it characterized by transient systolic dysfunction of the 
apical and/or midsegments of the left ventricle (Novo G. et al. 2014). 
We analyzed the role of a SNP rs17098707 ( L41Q) of the G-protein-coupled receptor 
kinase 5 (GRK5) in TTC patients and control. 
The purpose of this study was to assess the genetic susceptibility to TTC, to  favoure a 
better understanding of the pathogenesis of this peculiar syndrome,  that could allow the 
development of more appropriated preventive strategies and tailored treatment. 
Finally, in Chapter 9 it was evaluated the role of functional variants located in some 
cytokine genes to understand better the controversial mechanisms, by which cytokines 
underlie neoplastic transformation and progression. These studies are supported by 
strong evidences that both tumor and free stromal cells are able to produce cytokines 
that seem to affect the complex phenomena occurring at the tumour–host interface, thus 
leading to tumour. 
This study (Genetic determined expression of pro and anti inflammatory mediators 
influence the clinical history and response to chemotherapy in patients with Spo-
radic Colorectal cancer (CRC), Forte GI et al. Submitted) firstly, focused on the ge-
netic role of polymorphisms located on crucial pro-inflammatory and anti-inflammatory 
cytokine genes: -174G/C_rs1800795 (IL-6); +874A/T_rs2430561 (INF-γ); -
592A/C_rs1800872, -819C/T_rs1800871, -1082G/A_ rs1800896  (IL-10); 
R25P_rs1800471 (TGF-β), able to direct the immune system response, in the disease 
susceptibility. Secondly, we were interested to assess the immunological systemic 
movements caused both by the host-tumor interaction and by the chemotherapy treat-
ment, in the sporadic colorectal cancer. In particular, the chemotherapy effect was eva-
luated in the long term, waiting at least 20 days from the drug administration.  
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To this aim, we evaluated the expression level changes of some pro-inflammatory (IL-6, 
INF-γ, Cyclooxygenase (COX)-2), and anti-inflammatory (IL-10, TGF-β) type crucial 
cytokines produced by peripheral blood mononuclear cells (PMBC) in a group of pa-
tients having sporadic colorectal carcinoma across the period of their clinical manage-
ment. 
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ABSTRACT 
Colorectal cancer (CRC) is one of the highest cause of morbidity and mortality in West-
ern world. As it is known, a tight relation exists between the inflammation control ca-
pacity and cancer, in terms of susceptibility, tumorigenesis, progression and metastatic 
dissemination. Indeed, in the early steps of the cancerogenesis a genetically determined 
major systemic inflammatory capacity, due to polymorphisms of genes coding for in-
flammation regulation key molecules, could be primarily involved in cancer susceptibil-
ity and development as well as the response to chemotherapy. Here the effect of genetic 
polymorphisms located on crucial pro-inflammatory and anti-inflammatory cytokine 
genes (IL-6 -174G/C, rs1800795; INF-γ +874A/T, rs2430561; IL-10 -592A/C 
rs1800872, -819C/T rs1800871, -1082G/A rs1800896; TGF-β R25P, rs1800471) on the 
expression changes of some pro-inflammatory (IL-6, INF-γ, Cyclooxygenase (COX)-2), 
and anti-inflammatory (IL-10, TGF-β) factors produced by peripheral blood mononuc-
lear cells (PMBC) in a group of patients having sporadic colorectal carcinoma across 
the period of their clinical management was analysed. SNPs analysis shows a weak pro-
tective role against the development of sporadic CRC for the minor C allele of the G → 
C R25P; rs1800471 SNP, located within the signal peptide sequence of the TGF-beta 
gene (P: 0.021; Odds ratio: 0.3412; 95% C. I.: 0.1323 to 0.8800).   
An increase of IL-10 expression and an inverse behavior of IL-6 within 3 months from 
the chemotherapy treatment was observed. In particular a significant higher IL-10 
mRNA level characterize patients not free from disease (NFFD). Besides, we  always 
observed significantly lower IL-10 mRNA quantity in FFD patients, respect to NFFD 
ones, both if they underwent to chemotherapy or not (P: 00010, 00045, 0.328). Fur-
thermore, among patients undergone to chemotherapy, not FFD patients were characte-
rized by a significantly higher frequency of the IL-10 GCC haplotype, responsible of a 
higher mRNA production. In conclusion, overall our results confirms the involvement 
of TGF-β1 and IL-10 signaling pathway with CRC disease. Suggesting that analysis of 
IL-10 expression in PMBC might be an useful  marker in prediction of ongoing anti-
tumor response. 
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INTRODUCTION 
Colorectal cancer (CRC) is one of the highest cause of morbidity and mortality in West-
ern world. Among the factors involved in the pathogenesis of sporadic cases, eating ha-
bits, genetics, environment and inflammation are certainly focused, being the CRC fa-
milial cases, carriers of an hereditable genetic cause, only the 20% of overall patients. 
(Jemal A. et al. 2008). 
As it is known, a tight relation exists between the inflammation control capacity and 
cancer, in terms of susceptibility, tumorigenesis, progression and metastatic dissemina-
tion (Caruso C. et al. 2004; Terzić J. et al. 2010). A large debate exists on the role that 
immune mediators play across the tumor progression steps, so that the positive or nega-
tive influences of immune reactions should be evaluated case by case and contextua-
lized respect to the tumor steps (Vasto S. et al. 2008), also distinguishing the host local 
and systemic response (Caruso C. et al. 2009). 
Indeed, in the early steps of the cancerogenesis a genetically determined major systemic 
inflammatory capacity, due to polymorphisms of genes coding for inflammation regula-
tion key molecules, could be primarily involved in cancer susceptibility and develop-
ment. This relation is largely documented by several reported associations between 
functional pro-inflammatory polymorphisms located on genes coding for crucial cyto-
kines, such as Interleukin(IL)-6, Tumor Necrosis Factor (TNF)-α, IL-8, IL-10, Tumor 
growth factor (TGF)-β, and an increased susceptibility to develop colorectal cancer 
(Landi S. et al. 2003; Belluco C. et al. 2003; Crivello A. et al. 2006) and by the observa-
tions that patients with ulcerative colitis and Crohn’s disease are at increased hazard for 
developing colorectal cancer (Lakatos PL. et al. 2008).  
Actually, in the colorectal mucosa, cells of the innate immune system, such as neutro-
phils, mast cells, natural killer (NK) cells, dendritic cells (DC), and tumor-associated 
macrophages (TAM) can be easily detected and sustain the anti-tumor inflammation, 
through the synthesis of growth, remodeling or angiogenic molecules. Such evidences 
reveal a constitutive activation of molecules (NF-kB, STAT-3) implied in sustaining in-
flammatory pathways in colorectal cancer tissues (Sakamoto K. et al. 2009; Yu H. et al. 
2009). Other groups have demonstrated that IL-10 deficient mice are able to develop 
severe forms of atrophic gastritis, chronic enterocolitis and colon-rectum cancer 
(Hachimine D, et al. 2008). Moreover, the examination of normal colorectal mucosa 
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from patients with colon cancer reveals that it contains higher number of monocytes and 
neutrophils than controls (Roncucci L. et al. 2008). These multiple observations suggest 
a central role of inflammation in colorectal carcinogenesis. 
Activated innate cells are the first to migrate in the colorectal mucosa, where they are 
known to have a particular role in the orchestration of the response against tumor. Re-
cent studies on co-coltures with colon cancer and mononuclear cells demonstrated a 
tight interaction between each other, leading to an higher induced secretion of  both pro- 
inflammatory (TNF-α, IL-6, Interferon (INF)-γ, IL-1β) and anti-inflammatory (IL-10, 
IL-1ra) cytokines, tightly depending by the dose of tumor cells present into the culture 
(Bessler H. et al. 2010).  
Moreover, blood neutrophils, isolated from patients having inflammatory bowel diseas-
es were found to produce an increased quantity of inflammatory mediators in in-vitro 
coltures (Nikolaus S. et al. 1998), suggesting that the systemic immune system is 
stressed in patients suffering of chronic inflammation.  
Other studies observed that sera from patients with colorectal cancer showed increased 
IL-10 and sIL-2R levels in comparison with subjects with colorectal adenoma (Berghel-
la AM. Et al. 1997), while  IL-10 higher concentration was observed by Fortis and co-
workers in sera from patients with different kind of solid tumors at the same stage (IV) 
(Fortis C. et al 1996). Furthermore, IL-6 blood concentration seems to be associated 
with high circulating Carcino-Embryonic Antigen (CEA) and advanced stage in colo-
rectal cancer (Belluco C. et al 2000).   
On the other hand, the anti-inflammatory response might have a paradoxical effect have 
a role in the progression of cancer, contributing to immune-surveillance escaping me-
chanisms.  Particularly, two main actors in this scenario are the immune-suppressive cy-
tokines IL-10 and TGF-β, able to inhibit the maturation and activation of antigen-
presenting dendritic cells (DC), to promote the down-regulation of classes I HLA mole-
cules and NK cells activity, with the end effect of allowing the tumor to escape immune 
recognition and attack. In this sense, even though the infiltrated T-cells into sporadic co-
lon cancer tissues are generally associated to a good prognosis (Guidoboni M. et al. 
2001; Atreya I. et al. 2008), local immune-suppressive conditions could shift the im-
mune-balance inducing the differentiation of T regulatory subsets that might facilitate 
tumor progression and dissemination.  
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A field that it has not well explored is the relation between local and systemic response 
during the tumor evolution steps and therapy treatments is intriguing and not well eluci-
dated.  
A large rate of interaction between anti-cancer drugs and host immune adaptation exists. 
This fact is revealed by several studies which suggest that the progression of malignant 
tumors as well as the response to chemotherapy and targeted therapy is critically depen-
dent on the immunological parameters, often derived from the host immune system be-
havior. Chemotherapy rapidly attacks dividing cells, causing thrombocytopenia, neutro-
penia or leukocytopenia, but different cytokine profiling are reported in response to 
drugs mainly used in the treatment of cancer diseases. For example, Panis and co-
workers (2011) report an immediate plasmatic reduction of IL-1, IL-10 and TNF-α one 
hour later the treatment with doxorubicin, while they observe an increase of IL-10 blood 
level one hour later the administration of paclitaxel in breast cancer patients. On the 
other hand, Liu XL. and his group (2008) observed increased INF-γ and decreased IL-
10 blood levels after chemotherapy with Folfox4 (Oxaliplatin, Leucovorin, and Fluo-
rouracil) regimen in patients having gastric cancer.  
This study was designed to analyse both the role of genetic polymorphisms located on 
crucial pro-inflammatory and anti-inflammatory cytokine genes able to direct the im-
mune system response, in the in the sporadic colorectal cancer susceptibility. and  as-
sessment of the systemic immunological balance modification caused by the host-tumor 
interaction and by the chemotherapy treatment.  
To aim these goal we firstly typed -174G/C_rs1800795 (IL-6); +874A/T_rs2430561 
(INF-γ); -592A/C_rs1800872, -819C/T_rs1800871, -1082G/A_ rs1800896  (IL-10); 
R25P_rs1800471 (TGF-β) gene polymorphisms and then, evaluated the expression level 
changes of some pro-inflammatory (IL-6, INF-γ, Cyclooxygenase (COX)-2), and anti-
inflammatory (IL-10, TGF-β) cytokines produced by peripheral blood mononuclear 
cells (PMBC) in a group of patients having sporadic colorectal carcinoma across the pe-
riod of their clinical management.  
 
112 
 
 
MATERIALS AND METHODS 
Subjects 
A total of 120 patients affected by sporadic CRC and 280 healthy controls, age and sex 
matched, were enrolled in this study. The control group, constituted by informed volun-
teer persons, was recruited at the Biopathology and Medical and Forensic Biotechnolo-
gies Department of Palermo University, whereas the group of CRC patients was re-
cruited at the Surgical and Oncology Disciplines Department of Palermo University.  
Informed consent was requested to all the subjects enrolled. Table 1 reports, in a synop-
tic way, details describing our cohort of CRC patients.  
In details, our series of patients was so constituted: among female patients (44), 16 
(36.4%) had age at diagnosis ≥ 65 years old and 28 (63.6%) < 65 years old, whereas 15 
(34%) had right sited tumors and 29 (66%) left sited tumors. On the other hand, among 
male patients (76),  41  (53,8%) had age at diagnosis ≥ 65 years old and 35 (46,2%) < 
65  years old, moreover, 13 (16,9%) had right sited tumors and 63 (83,1%) left sited 
tumors. Furthermore, among patients with age at diagnosis <65 years old (63), 11 
(17.5%) had right sited tumors and 52 (81.5%) left sited tumors, whereas among pa-
tients with age at diagnosis ≥ 65 years old (57), 17 (29,8%) had right sited tumors and 
40 (70,2%) left sited tumors. 
 
 
Study design 
Specifically, for each patient enrolled, the blood samples collected were classified based 
on the following moments of harvesting: post- surgery (PS), < 3 months post-
chemotherapy (<3MPC),  >3 months post-chemotherapy (>3MPC). Then, the cytokine 
expression levels, evaluated by qPCR, were studied on the base of: 1) the timing of 
blood collection during the patient’s management, 2) the undergoing to a chemotherapy 
treatment, 3) the Duke stage, and 4) the freedom from disease at the moment of blood 
collection.  
In the end, it has been investigated the role of functional polymorphisms located on the 
IL-10 promoter (-592C/A_rs1800872; -819C/T_rs1800871; -1082G/A_rs1800896), 
structured in three characteristic haplotypes (GCC, ACC,ATA) (Turner DM. et al. 1997; 
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Eskdale J. et al. 1998), known to affect the promoter activity (Lio D. et al 2002), respect 
to the quantity of IL-10 mRNA produced in response to the chemotherapy treatment. 
These mRNA levels, conditioned by genetics, might be indicative of the type of an host-
tumor immune response and could give us prognostic indications about a better or 
worse response to chemotherapy. 
 
Sample Analyses 
Blood samples were collected and DNA was obtained from all the subjects recruited, 
whereas total mRNA was extracted from 24 healthy controls and 117 blood samples 
randomly obtained from a sub-group of patients according to the following moments of 
collection: post- surgery (PS), < 3 months post-chemotherapy (<3MPC), >3 months 
post-chemotherapy (>3MPC). Post-surgery' and post-chemo' blood collections have 
been performed, at least, 20 days later. Total RNA extracted from healthy controls has 
been used to obtain a calibrator for the relative quantification by the Comparative 
Cycles to Threshold (Ct) method. 
 
Nucleic acids extraction 
The blood specimens were collected in EDTA sterile tubes. Then, DNA molecules were 
extracted using a salting out protocol (Miller et al. 1988), resuspended in Tris–EDTA 
buffer and stored at -20°C. Instead, total mRNAs were exclusively obtained from fresh 
blood samples, following the PMBC recovery on Ficoll (Euroclone, UK) stratification. 
Then, total mRNA were purified by using silica-membrane columns (RNeasy Mini Kit, 
Qiagen, Germany), eluted in RNAse free water and stored at -80°C.  
 
SNPs genotyping 
Dedicated and pre-made competitive allele specific PCR (Polymerase Chain Reaction) 
assays (KASPar), developed by KBioscience (England) were used to perform the Allel-
ic Discrimination tests for the typing of the following functional polymorphisms: -
174G/C_rs1800795 (IL-6); +874A/T_rs2430561 (INF-γ); -592A/C_rs1800872, -
819C/T_rs1800871, -1082G/A_ rs1800896 (IL-10); R25P_rs1800471 (TGF-β). 
In details, KASPar SNP genotyping method is an end-point PCR, based on a fluorescent 
FRET (Fluorescent Resonance Energy Transfer) system. A mixture of unlabeled pri-
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mers are specifically designed on the sequence of interest and it consists of: 1) two al-
lele-specific forward primers, having a terminal common tag at the 5’end; 2) a common 
reverse primer; 3) two small oligonucleotides complementary to the 5’ tag regions of 
the allele-specific forward primers, labeled with two different fluorophores (FAM, 6-
carboxy-fluorescein; VIC, 2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein) 4) 
two small oligonucleotides labeled with quenchers at the 3' end, complementary to those 
described in section 3.  
Unlabeled primers were specifically designed on demand by KBioscience (England).  
With the advancing of PCR cycles the labeled oligonucleotides bind, in a competitive 
way, the tag regions of forward primers rather than the quenching tags and will remain 
incorporated in the new synthesis molecules, releasing an increasing signal.  
Briefly, 10 ng of DNA for each sample were used in an end-point KASPar PCR reac-
tion, containing  optimized master mix and the specific primer assay mix for each SNP, 
according to manufactory protocol in a final volume of 8 µl. Then, the amplification 
reactions were performed in the Master Cycler Gradient (Eppendorf, Germany), using a 
standard program consisting of the following cycles:  1) 94 °C for 15’;  2) 94 °C for 
20”;  3) Touchdown 65-57 °C per 60”;  4) Repeating steps 2 and 3 for 10 cycles (Drop - 
0.8°C/for each annealing cycle);  4) 94 °C for 20”; 5) 57 °C per 60”; 6) Repeating steps 
4 and 5 for 26 cycles. Finally, plates were scanned at the temperature of 4°C in a 7300 
Real-Time ABI Prism PCR System (Applied Biosystems, USA) to register the fluores-
cence emission for each well, then samples were graphically grouped by the SDS soft-
ware vs.1.3 (Applied Biosystem, USA) in three genotypic clusters (homozygous and he-
terozygous subjects), easily recognizable in the Allelic Discrimination plot on the basis 
of the two probe’s fluorescence intensity emission. 
Furthermore, following the genotype determination for each IL-10 SNP, haplotypes 
were easily deduced respect to the three possible SNP combinations  (GCC, 
ACC,ATA). 
 
cDNA synthesis and Real Time quantification 
cDNA molecules were synthesized by using SuperScript® II Reverse Transcriptase (In-
vitrogen, USA), according to manufactory protocol. Briefly, 500 ng of total RNA were 
placed in the presence of 1 µl of oligo-dT (500 µg/ml) and 1 µl of dNTP Mix (10 mM) 
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and the mixture, so constituted, has been warmed at the temperature of 65°C in order to 
eliminate mRNA secondary structures. Then, First- Strand Buffer 5X, 2 µl of 0,1M 
DDT (Dithiothreitol) and 200 U of Reverse Transcriptase were added in a final volume 
of 25 µl and the mixture incubated at 42°C for 50’.  
Subsequently, 5 µl of the reverse transcription reaction has been used in Quantitative 
Real Time PCR (qPCR) assays, performed to quantify the relative mRNA levels in 
CRC patients by using the Comparative Ct method. In particular, we determined the 
fold change expression of target genes of interest (IL-6, INF-γ, COX-2, IL-10, TGF-β) 
normalizing respect to the housekeeping gene L13. Moreover, for the purpose of our 
study, a ∆Ct mean value, calculated as the difference between the Ct mean value of the 
target gene and that one of the housekeeping gene from a total of 24 healthy subjects, 
has been used as calibrator (∆Ctcalibrator). 
TaqMan probes and specific PCR primers have been designed for each sequence of in-
terest, taking care to design primers on the sides of a long intronic sequence, in order to 
avoid amplification of such contaminant DNA molecules. Each Probe was 3’ labeled 
with BHQ1 (Black Hole Quencher 1) and 5’ labeled with FAM (target genes) or VIC 
(housekeeping gene) fluorophore. 
Table 2 reports the details of primers pairs and probes sequences used in the Real Time 
assays.  
Reactions have been prepared in a final volume of 25 µl in the presence of 300 mM 
probe, 900 mM primers, 0,5 µM ROX and 1X Platinum Quantitative PCR Super Mix-
UDG (Invitrogen, USA) and run in a ABI Prism 7300 (Applied Biosystem, USA), uti-
lizing a standard amplification program: 1) 2’ at 50 °C; 2) 10’ at 95°C; 3) 15” at 95°C; 
4) 30” at 60°C; 5) Repeating steps 3 and 4 for 39 cycles.   
 
Statistical analysis 
The allele and genotype frequencies of the SNPs analyzed were evaluated by 3x2, 2x2 
or nxn tables and the differences between the observed and expected distributions be-
tween the groups of subjects considered was assessed by applying the Pearson Chi-
Square test or the Fisher’s Exact Test.  It was accepted a significance value of P ≤ 0.05. 
The Hardy Weinberg equilibrium was tested on the  observed frequencies registered for 
116 
 
the control' population, using the Pearson Chi-Square test. All the analysis were per-
formed with the SPSS software (SPSS, Chicago, Illinois). 
The Mann-Whitney nonparametric test was used in every cases where it was necessary 
to evaluate differences between the observed and expected medians from distributions 
of two series of measured values.  In alternative, the Kruskal-Wallis test was utilized for 
the comparison of the medians obtained from more than two series of distributions, 
while the Dunn's Multiple Comparisons test has been used for the multiple comparison 
of pairs of distributions.  
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RESULTS  
Association analysis 
As a first step, we analyzed the genetic contribute of polymorphisms known to affect 
the cytokine mRNA production to the susceptibility of sporadic colorectal cancer dis-
ease.    
Particularly, we have chosen selected crucial cytokines (IL-6, INF IL-10, TGF-β) able 
to profoundly influence the immune microenvironment surrounding neoplastic cells. we 
studied the genotypic and allelic frequencies distribution between patients and healthy 
subjects of the following polymorphisms of IL-6           -174G/C (rs1800795),  INF-γ 
+874A/T (rs2430561),  IL-10-592A/C (1800872) -819C/T (rs1800871)            -
1082G/A (rs1800896) and TGF-β) R25P (rs1800471) have been evaluated. 
For each polymorphism, it has been possible to study a random selection of samples 
from the total number of subjects recruited in our series of 120 patients and 280 healthy 
controls. The Hardy Weinberg equilibrium, applied to the  observed frequencies of the 
control' population, was always respected. 
Table 3 reports the results of this association study. No significant genetic contribute 
has been observed for 5 out the 6 SNPs tested. Indeed, a significant different allelic dis-
tribution between patients and controls has been observed for the polymorphism G → 
C, responsible of an arginine vs. proline missense change (R25P) in correspondence of 
the codon 25 of the coding region of the TGF-β gene (P: 0.021; Odds ratio: 0.3412; 
95% C. I.: 0.1323 to 0.8800).  By this analysis, a weak protective role would emerge for 
the minor allele C in the susceptibility  to the disease. 
  .   
The chemotherapy effect 
In order to study long term effect of chemotherapy on the immunological systemic bal-
ance of colorectal cancer patients, we analyzed the mRNA levels of some pro-
inflammatory (IL-6, INF-γ, Cyclooxygenase (COX)-2, and anti-inflammatory (IL-10, 
TGF-β) type crucial cytokines produced by peripheral blood PMBC after at least 20 
days from a dose administration. This time lapse is considered sufficient for the return-
ing to an immunological steady state, giving us the possibility to observe only late ef-
fects produced by the chemotherapy drugs. Then, we investigated the systemic immune 
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system behavior within three months and after, at least, three months from the last che-
motherapy dose.   
As it is shown in table 4, the effect of a chemotherapy treatment administration results 
in a significant increase of the IL-10 mRNA produced by PMBC, observable when the 
samples were collected within 3 months from the chemotherapy administration 
(<3MPC, 26 samples). 
In fact, comparing the median value of IL-10 mRNA between this group of 26 samples 
(<3MPC), respectively with: a) the group of 44 samples collected after, at least, 3 
months from the last administrated dose of chemotherapy (>3MPC); b) the group of 38 
samples collected after, at least, 3 months from the last administrated dose of chemothe-
rapy that were free from disease at the time of the blood collection (>3MPC FFD), c) 
the group of 72 samples, including those collected after, at least, 3 months from the last 
administrated dose of chemotherapy and those performed after the tumor removal by 
surgery (>3MPC + PS), the IL10 mRNA levels were, always, significantly higher in the 
first group of samples analyzed within 3 months after the last chemotherapy dose 
(<3MPC), P-values:  a) 0.0007, b) 0.0001, c) 0.0062 respectively. 
Note that, the three groups chosen for the evaluation of the inflammatory status pro-
duced within three months from the chemotherapy administration, were preferred be-
cause, in every cases, we could suppose that they, presumably, underwent to a re-
establishment of the immune balancing, due to a sufficient time elapsed from the treat-
ment (more than three months) or from the surgery (at least 20 days later), or because 
they were already free from disease.  
On the other hand, if one considers the comparison between the full group of patients 
who underwent to a chemotherapy treatment, regardless of timing of treatment (CT, 70 
samples), with those not chemo-treated who underwent to the blood collection follow-
ing the surgical tumor removal (PS, 28 samples), the significance is lost, sign of a re-
turning toward an IL10 mRNA serum normalization few months later, which justify a 
balancing  of IL-10 mRNA quantity inside the comprehensive group of patients that un-
derwent to the blood collection before and after three months from the last chemothera-
py dose.   
Also, it can be observed that the IL-6 mRNA levels move following an inverse behavior 
to those ones of IL-10 mRNA, although the differences are never significant. In particu-
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lar, we observed lower levels of IL-6 mRNA within 3 months from the last dose of 
chemotherapy (<3MPC), probably caused by the IL-10 higher anti-inflammatory effect, 
whereas, the IL-6 levels tend to rise in the groups analyzed more than three months 
away from the chemotherapy administration (>3MPC). Instead, no relevant change is 
recorded for Cox-2, IFN-γ and TGF-β mRNAs. 
The host-tumor interaction effect 
In order to study the relation between the presence of an active tumor mass and a conse-
quent systemic immune modulation, we firstly investigated the cytokine mRNA serum 
levels according to the Duke’s stage. In a first approach we considered if a trend of cy-
tokine expression could exist across the progression of the disease from the A to the D 
stage. No significant differences it was observed from the comparison of the medians of 
the distributions analyzed, neither it was observed significant difference from the com-
parison of medians from pairs of distributions (data not shown). Then, we evaluated the 
difference in the median values of the cytokine mRNA's quantity distributions between 
the earliest stages (A-B) of the disease versus the latest stages (C-D). No significant dif-
ference was assessed between earlier and later Duke’s stages for none of the crucial cy-
tokine analyzed. Table 4.    
Subsequently, we investigated the immune modifications based on the presence/absence 
of an active disease.  In particular, in our series 65 samples derived from patients free 
from disease (FFD) at the time of the blood collection, while 33 from patients not free 
from disease (not FFD). This approach revealed that the IL-10 mRNA blood levels were 
significantly higher in the group of patients not free of disease (P-values: 0.0010). 
However, it can be assumed that the higher levels of IL-10 could be affected by a mod-
ulator effect resulting from the chemotherapy administration, as the above results sug-
gest. Nevertheless a biological effect due to the presence of an active tumor mass could 
be also hypothesized. Indeed, looking among the patients not-free from disease (not 
FFD) only one third (11/33) had undergone chemotherapy and the IL-10 levels were 
particularly high (3.5 ± 4) in this small subset of patients, as to underline the result of 
double effect mediated both by the chemotherapy treatment and by the biological host-
tumor interaction. Moreover, if one would compare the  IL-10 mRNA blood levels of 
this small group of chemo-treated patients not free from disease (CT: not FFD, 11 sam-
ples) with that of treated patients free of disease (CT: FFD, 23 samples), or either with 
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the group of patients not treated with chemotherapy free from disease (not CT FFD, 14 
samples), the IL-10 mRNA levels were significantly higher in the first group in both the 
comparison (P: 0.0045;  P: 0.00328).  In particular, the last group of comparison can be 
considered to be constituted by patients sharing the opposite condition: to be not chemo-
treated and disease free.  
On the other hand, no significant change has been observed for the of IL-6, COX-2, 
IFN-γ and TGF-β mRNA levels in the group of patients described in this section. 
Finally, we wanted to investigate if the individual genetic background, controlled by the 
IL-10 haplotypes, could also be implicated to generate the observed higher IL-10 levels 
in response to therapy. 
As it is shown in table 5, among the chemo-treated patients the GCC haplotype (high 
IL10 producer) has been observed to be significantly higher represented in patients not 
free of disease, respect to the ACC / ATA haplotypes (lower producers of IL-10) (GCC: 
21 vs. ACC / ATA: 15; ); on the other hand, the ACC / ATA haplotypes are significant-
ly prevalent among patients free from disease respect to the GCC one (39 vs.21) (P: 
0.034). The genetic data suggest that a greater capacity to produce IL-10 is prognosti-
cally not favorable for the resolution of the disease after treatment (Odds ratio: 2,6; 95% 
C.I. from 1,11 to 6.077). In addition, the genetic data justify the observation of a partic-
ularly increased IL-10 expression in patients receiving chemotherapy not free of dis-
ease. 
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DISCUSSION 
Although immune therapy is still retained not very effective and tumors are mainly 
fought by surgical removal and individualized therapeutic treatments, however systemic 
and local cytokines strongly modulate the anti-tumor response, conditioning the disease 
outcomes. To this regard, the individual genetic contribute to the immune system anti-
cancer effort could be considered fundamental.  This study aimed to clarify the relations 
between a genetic determined immune control capacity and the cytokine expression pat-
tern, able to interfere with sporadic colon cancer disease in terms of susceptibility and 
prognosis. 
To this aim, we retained important to, firstly, analyze the contribute to susceptibility of 
functional polymorphisms affecting the promoter activity and the transcription rate of 
inflammatory and anti-inflammatory cytokine genes such as (-174G/C_rs1800795 (IL-
6); +874A/T_rs2430561 (INF-γ); -592A/C_rs1800872, -819C/T_rs1800871, -
1082G/A_ rs1800896 (IL-10); R25P_rs1800471 (TGF-β), crucial in directing the type 
and the strength of response.  As already described, no associations were observed be-
tween 5 out the 6 analyzed polymorphisms and the development of sporadic CRC in our 
cohort of Sicilian patients for which genotype and allelic distributions were not diffe-
rently distributed between patients and controls.  However, a weak protective role 
emerged for the minor C allele of the G → C R25P; rs1800471 SNP, located within the 
signal peptide sequence of the TGF-β gene (P: 0.021; Odds ratio: 0.3412; 95% C. I.: 
0.1323 to 0.8800).   
Recent genome-wide association studies have highlighted the important contribute of 
numerous SNPs belonging to the TGF-β superfamily, which may be responsible of a si-
zeable proportion of colorectal cancer cases (Tomlinson IP. 2008; Tomlinson IP. 2009). 
Previously, we had studied the polymorphism rs1800470, responsible for a Leu→Pro 
substitution in correspondence of codon 10, forming haplotype with the rs1800471 SNP 
studied in this paper (Crivello A. et al. 2006). In that study, we had observed a signifi-
cant increased risk for the major allele (cod10-Pro) (P: 0.011; Odds ratio: 2.62 (1.40–
4.91). Therefore, taking together both the results, we could suggest a weak  protective 
role for the haplotype constituted by the two minor alleles (cod10-Leu/cod25-Pro). This 
haplotype represents the 12.8% in the Indian population according to Manchanda PK. 
(2008) and co-workers, whereas in the study conducted by Jin Q and co-workers (2004) 
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on Polish and Finnish populations, it is registered with a percentage close to zero, as 
these European populations were characterized by a low percentage of the C allele fre-
quency for the cod25 SNP, similarly to our finding (0.03%). However, our cod25 SNP 
frequencies are confirmed by many other groups (Gendzekhadze NS. 2006, Alakulppi 
K. 2004; Park 2004).  
These observations suggest a different weight of TGF-β SNPs on CRC susceptibility, 
strongly dependent by the SNP penetrance on a certain population.  
Then, in order to evaluate the immune response in prognostic terms, we aimed to cha-
racterize the cytokine PMBC expression profile (IL-6, INF-γ, COX-2, IL-10, TGF-
β) describing the host-tumor relationships and the response to therapeutic treatments.  
To reach this aim, we have chosen to categorize patients according to the moment of the 
blood collection (PS, <3MPC, >3MPC), recording, at that time, the clinical condition in 
terms of Duke’s stage and freedom from disease. This approach allowed us to easily 
compare  sub-groups of patients with each other for the PMBC mRNA quantity, as CRC 
is a very heterogeneous disease, characterized by a high clinical and molecular variabili-
ty, that do not allow to analyze the patients as a single group (Sheffer M. et al. 2009; 
Winder T. et al. 2010).  
Other groups investigated the immediate effect of chemoterapy administration on the 
immune system, finding different cytokine patterns  (Panis C. 2011, Liu XL. 2008), 
however this is, to our knowledge, the first time it is chosen to look at long term im-
mune system modulation induced by chemotherapy.  
Our results make evident an increase of IL-10 within 3 months from the chemotherapy 
treatment. In our study, all the blood collections were performed after, at least, 20 days 
from the administration of a chemotherapy dose or surgery, a time lapse sufficient to de-
fine this one  as a long term effect mediated by the treatment. In addition, the IL-10 ex-
pression seems to return to normalization few weeks later, as it is suggested by the ob-
servation that no significant difference occurs in the comparison between patients ana-
lyzed post-surgery (PS, 28 samples) and chemo-treated subjects regardless of timing of 
treatment (CT, 70 samples).  
On the other hand, we also detected an IL-6 inverse behavior respect to the IL-10 
movements, even if the results are not significant. This observation could be justified by 
the IL-10 suppressive effect, as it was demonstrated by Li and co-workers (2010), 
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which have proved the IL-10 involvement into the monocyte/macrophage IL-6/Stat-3 
signaling down-regulation, a pathway enhancing the IL-6 itself synthesis mainly impli-
cated in the tumor cells migration.  
Our results are not filtered according to the type of adjuvant regimen used, both for the 
fact that the regimens commonly administrated in the treatment of colorectal cancer 
were mainly based on the use of 5-fluorouracil (5-FU) plus leucovorin (LV, also called 
Folinic acid, FA) in combination with other drugs: oxaplatin (FOLFOX4/6), irinotecan 
(FOLFIRI, IRIFAF), adriamycin (MACHOVER), both because combinations of these 
regimens could be administrated in different times to the same patient, so that the num-
ber of samples obtainable post-filtering would be reduced and statistically not suitable.  
Moreover, radiotherapy treatments and biologic targeted therapies were excluded from 
our analysis.   
Then, in order to verify the hypothesis that cytokine gene expression patterns could be 
indicative of ongoing anti-tumor response, we investigated this topic looking at the rela-
tion with the presence of an active tumor mass and with the disease stage. 
Several groups described altered IL-6, TNF-α, IL-2, IL-4, IL-10 and TGF-β in sera of 
CRC patients. However, many of them studied these marker quantities in comparison to 
controls. Indeed, the group of Csiszár A. (2004) detected more IFN-γ transcripts in 
PBMC samples from patients with colorectal cancer than in healthy controls, while Tsu-
shima H. (2004) and co-workers observed significantly higher plasma TGF-β1 levels in 
patients with colorectal cancer than in normal controls. Some other groups tried to cor-
relate the cytokine expression pattern with the disease evolution. The group of Berghel-
la AM. (1997) showed increased IL-10 and sIL-2R levels in patients with colorectal 
cancer in comparison with subjects with colorectal adenoma, while the group of Belluco 
C. (2000) associated IL-6 blood concentration with high circulating CEA in advanced 
stage in colorectal cancer.  
Here, we lacked to observe significant cytokine movements according to the Duke stage 
progression, but we revealed a significant higher IL-10 mRNA quantity among not free 
from disease (NFFD) patients respect to FFD ones. Considering that patients with a re-
maining tumor mass could still be under chemo-therapy treatment, we evaluated pa-
tients not FFD that also underwent to chemotherapy. The finding of particularly high 
PMBC IL-10 mRNA levels in this group of subjects suggest a double effect mediated 
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both by the treatment and by the presence of an active mass. Besides, we  always ob-
served significantly lower IL-10 mRNA quantity in FFD patients, respect to not FFD 
ones, both if they underwent to chemotherapy or not (P: 00010, 00045, 0.328). Our 
findings are supported by PBMC/ CRC cells co-cultures experiments made by the group 
of Blesser H. (2010), which revealed a more pronounced pro- and anti-inflammatory cy-
tokine production depending upon an increased malignant cells quantity in the culture. 
Furthermore, among patients undergone to chemotherapy, not FFD patients were cha-
racterized by a significantly higher frequency of the IL-10 GCC haplotype, responsible 
of a higher mRNA production, respect to FFD ones, which, instead, had a major percen-
tage of ACC/ATA haplotypes (P: 0.034), an observation suggesting the IL-10 SNPs as 
prognostically informative genetic markers. 
It can be supposed that these increased IL-10 circulating level, genetically affected, may 
contribute to enhance the tumor cells escaping from immune surveillance, however, IL-
10 is known to play also a protective role into reduce the inflammatory molecules le-
vels, inducing local inflammation, angiogenesis and cell migration (Li YY. et al. 2010; 
Nikolaus S. et al. 1998).  
Specifically, IL-10 is known to play a double role in tumor diseases (Terzić J. et al. 
2010), as if it is known to play a protective in the reduction of inflammation and suscep-
tibility to tumor transformation (Hachimine D. et al. 2008), it seem to have a negative 
role in tumor progression later, as the results of this study confirm. 
In conclusion, overall our results make evident the immune system role in the condi-
tioning of susceptibility and disease's outcomes, revealing, one more time, the associa-
tion of TGF-β1 signaling pathway with CRC disease (Bellam M. et al. 2010) and find-
ing in IL-10 both a genetic and a circulating marker of ongoing anti-tumor response. 
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Table 1. Patients’ features 
 
Patients’ Features   Total N (%) 
Age at diagnosis 
<65 years old  
≥65 years old 
 
63 (52,5) 
57 (47,5) 
Gender 
Female  
Male 
 
44 (36,7) 
76 (63.3) 
Tumor Location 
Right 
Left 
 
28 (23,3) 
92 (76,7) 
Duke’ Stage 
A and B 
C and D 
 
58 (48.3) 
62 (51.7) 
Chemotherapy 
Yes 
No 
 
81 (67,5) 
39 (32,5) 
Freedom from disease (FFD)*  
Yes  
No 
 
77 (65.8) 
40 (34.2) 
Blood collection time* 
post- surgery (PS) 
< 3 months post-chemotherapy (<MPC) 
>3 months post-chemotherapy (>MPC) 
 
35 (30.0) 
30 (25.6) 
52 (44.4) 
          
 
 
* Blood collections were randomly obtained (when available) from a sub-group of patients during some 
steps of their own clinical management (PS; <3 MPC; >3 MPC). The FFD has been assessed at the time 
of blood collection.  
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Table 2. Primers pair and probes used for the relative quantification of IL-10, INF-g, IL-6, TGF-b, Cox-
2 PBMC levels  
L13 primers pairs and probe   
        L13 Forward:      5’-GCTGGAAGTACCAGGCAGTGA- 3’ 
        L13 Reverse:       5’-ACCGGTAGTGGATCTTGGCTTT- 3’  
        L13 Probe:         5’VIC -TCTTTCCTCTTCTCCTCCAGGGTGGCT- BHQ1_3’ 
IL-10 primers pairs and probe   
        IL10 Forward:    5’-CTGAAGACCCTCAGGCTGAG- 3’ 
        IL10 Reverse:      5’-GCATTCTTCACCTGCTCCAC- 3’  
        IL10 Probe:        5’FAM -ACGGCGCTGTCATCGATTTCTTCCC- BHQ1_3’  
INF-γ primers pairs and probe   
        INFγ Forward:   5’-TTCGGTAACTGACTTGAATGTCC- 3’ 
        INFγ Reverse:     5’-GACAACCATTACTGGGATGCTC- 3’ 
        INFγ Probe:       5’FAM –CGACCTCGAAACAGCATCTGACTCCT- BHQ1_3’ 
IL-6 primers pairs and probe   
        IL-6 Forward:    5’-ATTGACAAACAAATTCGGTACATCC- 3’ 
        IL-6 Reverse:      5’-GGACTTGGAAGGTTTCTACCG- 3’ 
        IL-6 Probe:        5’ FAM –TGAAAGCAGCAAAGAGGCACTGGCA- BHQ1_3’ 
TGF-β primers pairs and probe   
      TGF-β Forward:   5’-GCCTGAGGCCGACTACTAC- 3’ 
      TGF-β  Reverse:    5’-TGTGTACTCTGCTTGAACTTGTC- 3’  
      TGF-β Probe:       5’ FAM -CCAAGGAGGTCACCCGCGTGCTAAT- BHQ1_3’ 
Cox-2 primers pairs and probe   
     Cox-2 Forward:      5’-GCCTCCTTCAGCTCCACAG- 3’ 
     Cox-2  Reverse:       5’-GGTGGGAACAGCAAGGATTTG- 3’  
     Cox-2  Probe:         5’FAM -ACGCCCTCAGACAGCAAAGCCTACC- BHQ1_3’ 
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Table 3. Genotype frequencies in CRC patients and healthy controls 
 
Table 3    Con-
trols 
Cases P 
(3x2) 
P allelic 
(2x2) IL-10 (-592 A/C  rs1800872) 
0.785 0.527 
CC 80 (54.0%) 45 
(49.4%) AC 58 (39.2%) 39 
(42.9%) AA 10 (6.8%) 7 (7.7%) 
IL-10  (-819C/T  rs1800871) 
0.901 0.694 CC 
105 
(50.2%) 
43 
(47.8%) CT 90 (43.1%) 40 
(44.4%) TT 14 (6.7%) 7 (7.8%) 
IL-10  (-1082G/A  rs1800896) 
0.462 0.306 AA 
108 
(40.3%) 
36 
(36.4%) AG 120 
(44.8%) 
43 
(43.4%) GG 40 (14.9%) 20 
(20.2%) IL-6 (-174 G/C  rs1800795) 
0.370 0.250 GG 
125 
(45.5%) 
52 
(53.6%) GC 110 
(40.0%) 
32 
(33.0%) CC 40 (14.5%) 13 
(13.4%) INF-γ (+874 A/T  rs2430561) 
0.725 0.716 TT 70 (27.3%) 22 
(27.8%) AT 128 
(50.0%) 
36 
(45.6%) AA 58 (22.7%) 21 
(26.6%) TGF-β (R25P  rs1800471) 
0.080 0.021 GG 200 
(84.4%) 
77 
(93.9%) GC 34 (14.3%) 5 (6.1%) 
CC 3 (1.3%) 0 (0%) 
 
Genotype frequencies observed in our Sicilian healthy cohort and in our sporadic CRC 
group of patients.  
It was accepted a significance < 0.05.  
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Table 4. Analysis of mRNA expression in relationship to the chemotherapy effect and the Host-tumor interaction 
 
I° group 
(N) 
II° 
group 
(N) 
P-
val-
ue 
I° group 
(N) 
II° 
group 
(N) 
P-
val-
ue 
I° group 
(N) 
II° 
group 
(N) 
P-
val-
ue 
I° group 
(N) 
II° 
group 
(N) 
P-
val-
ue 
I° group 
(N) 
II° 
group 
(N) 
P-
val-
ue 
 
            IL-10              IL-6            COX-2 
            INF-γ               TGF-β 
The chemotherapy ef-
fect 
     
<3MPC vs  >3MPC 1.59 ± 3.7 (26) 0.59 ± 0.2 (44) 0.0007 1.9 ± 1.39 (27) 2.16 ± 0.96 (50) 0.88 0.17 ± 2.15 (20) 0.2 ± 2.15 (41) 0.40 1.5 ± 2.23 (29) 1.72 ± 1.47 (50) 0.87 0.90 ± 1.08 (27) 1.17 ± 0.81 (50) 0.80 
<3MPC vs  >3MPC FFD 1.59 ± 3.7 (26) 0.52 ± 0.2 (38) 0.0001 1.91 ± 1.39 (27) 2.47 ± 0.99 (42) 0.64 0.17 ± 2.15 (20) 0.26 ± 2.58 (34) 0.36 1.5 ± 2.23 (29) 2.24 ± 4.8 (42) 0.49 0.90 ± 1.08 (27) 1.17 ± 0.84 (42) 0.85 
<3MPC vs >3MPC + PS 1.59 ± 3.7 (26) 0.94 ± 0.6 (72) 0.0062 1.91 ± 1.39 (27) 2.03 ± 0.98 (80) 0.8 0.17 ± 2.15 (20) 0.27 ± 1.35 (70) 0.34 1.5 ± 2.23 (29) 1.2 ± 1.33 (84) 0.75 0.90 ± 1.08 (27) 1.31 ± 1.03 (84) 0.67 
CT vs PS 1.03 ± 1.4 (70) 1.28 ± 1.59 (28) 0.19 2.12± 0.78 (77) 1.78 ± 3.3 (31) 0.99 0.19 ± 1.58 (62) 0.41 ± 1.21 (29) 0.60 1.6 ± 2.69 (80) 0.75 ± 2.5 (34) 0.13 1.08 ± 0.64 (77) 1.55 ± 2.22 (34) 0.13 
The Host-tumor interac-
tion 
               
DS: (A-B vs C-D) 1.15 ± 0.29 (21) 1.34 ± 1.95 (28) 0.80 2.2± 1.97  (25) 1.7 ± 5.4 (30) 0.56 0.16 ± 0.98 (22) 0.31 ± 1.37 (26) 0.98 0.55 ± 1.65 (26) 0.9 ± 0.86 (31) 0.52 0.77 ± 0.77 (28) 0.74 ± 2.17 (28) 0.65 
FFD vs not FFD  0.79 ± 0.47 (65) 
1.75 ± 
1.48 (33) 
0.0010 1.16 ± 1.53 
(72) 
1.61 ±1.25 
(37) 
0.54 0.27 ± 1.57 
(61) 
0.24 ± 1.28 
(30) 
0.28 1.2 ± 2.9  
(75) 
1.22 ± 1.87 
(40) 
0.61 1.25 ± 0.83 
(77) 
1.08 ± 1.87 
(35) 
0.66 
CT:  FFD  vs not FFD 0.64 ± 1.28 (23) 3.5 ± 4  (11) 0.0045 2.5 ± 1.25 (26) 1.6 ± 2.06 (13) 0.87 0.34 ± 1.84 (21) 0.39 ± 0.54 (12) 0.92 0.95 ± 1.56 (28) 0.90 ± 1.8 (13) 0.48 0.74 ± 0.75 (27) 0.72 ± 4.9 (12) 0.65 
Not CT FFD vs CT not FFD  1.15 ± 0.33 (14) 3.5 ± 4  (11) 0.0328 2.07 ± 2.7 (15) 1.6 ± 2.06 (13) 0.93 0.19 ± 0.77 (14) 0.39 ± 0.54 (12) 0.67 0.42 ± 0.24 (15) 0.90 ± 1.8 (13) 0.065 0.95 ± 1.17 (17) 0.72 ± 4.9 (12) 0.999 
 
Data are expressed as median ± SEM. Inside brackets the number of samples involved. Significance has been calculated by Mann-Withney test.  
Abbreviations: PS: < 3 months post-chemotherapy;  <3MPC: < 3 months post-chemotherapy;  >3MPC: >3 months post-chemotherapy; FFD:  free from disease; DS: Duke Stage; CT: 
Chemo-Treated 
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Table 5 IL-10 Haplotype effects on chemotherapy response 
 
Chemo-treated patients Haplotype 1 
GCC 
Haplotype 2/3 
ACC/ATA 
Not Free from disease 
(n.18) 21 (58.3%) 15 (41.7%) 
Free from disease 
(n.30) 21 (35.0%) 39 (65.0%) 
 
Fisher's Exact Test on 2x 2 table.  P: 0.034. Odd Ratio: 2,6 (95% C.I. from 1,11 to 
6.077) 
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CHAPTER 10 
 
 
Summary and general discussion 
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The extraordinary increase of the expected life span in developed countries underscore 
the importance of studies on ageing and longevity and the need for the prompt spread of 
knowledge about ageing in order to satisfactorily decrease the medical, economic and 
social problems associated to advancing years, because of the increased number of indi-
viduals not autonomous and affected by invalidating pathologies. 
Centenarians are equipped to reach the extreme limits of human life span and, most im-
portantly, to show relatively good health, being able to perform their routine daily life 
and to escape fatal age-related diseases. Thus, they are the best example of extreme lon-
gevity, representing selected people in which the appearance of major age-related dis-
eases, such as cancer, and cardiovascular diseases among others, has been consistently 
delayed or escaped.  
Aging is a post-maturational process that, because of a diminished homeostasis and in-
creased organism vulnerability, causes a reduction of the response to environmental 
stimuli. The progressive decrease in physiological capacity and the reduced ability to 
respond to stresses lead to increased susceptibility and vulnerability to disease. Thus, 
mortality due to all causes increases exponentially with aging.  
Aging involves all the cells, tissues, organs, and organisms and is modulated by external 
factors. 
Ageing is accompanied by chronic low-grade inflammation state clearly showed by 2–
4-fold increase in serum levels of inflammatory mediators such as cytokines and acute 
phase proteins in aged population, which act as predictors of mortality independent on 
pre-existing morbidity. 
So far, we believe this is the most important cause of the elderly pro-inflammatory sta-
tus that, interacting with the genetic background, potentially triggers the onset of age-
related inflammatory diseases as atherosclerosis, cancer,  (Franceschi et al., 2000a,b; De 
Martinis et al.). 
The individual genetic background and the eventual influence of counteracting cyto-
kines, associated with different degrees of control of the inflammatory response, could 
therefore play a determining role in the onset of age-related diseases and in the 
achievement of advanced age in the absence disease. 
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Genetic variations located within the promoter regions of pro-inflammatory and regula-
tory cytokines could influence inflamm-ageing and the susceptibility to age-related dis-
eases. 
The Metabolic Syndrome (MS) is a clinical condition characterized by the simultaneous 
presence of more alterations in one individual  , mainly of metabolic origin, that directly 
increases  the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mor-
tality. 
It further increases with age, with an incidence of 44% in the population aged between 
60 and 69 years (Ford ES. Et al.2002).  
MS is a state of chronic low grade inflammation as a consequence of complex interplay 
between genetic and environmental factors. Insulin resistance (IR), visceral adiposity, 
atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, elevated blood 
pressure, hyper coagulable state, and chronic stress are the several factors which consti-
tute the syndrome. 
It can be the basis for the emergence of many age-diseases.  
This association could be due to the link between IR and inflammation, in fact, the same 
mechanisms that cause the IR determine both the synthesis and self-maintenance of pro-
inflammatory cytokines and thus the chronic and persistent inflammatory response that 
characterizes the inflammaging. 
It is not surprising that some studies have found an association between the metabolic 
syndrome and the development of cancer (Kreger BE et al. 1991), in particular of the 
Colon-Rectum Cancer (CRC); in addition to an increased risk of diabetes and cardi-
ovascular disease (Ninomiya JK et al. 2004). 
In this particular context, knowledge of genes polymorphisms, encoding cytokines, is a 
tool of extreme importance, not only for understanding the mechanisms underlying the 
pathogenesis of age related diseases, but also for future customization of personal 
treatment protocols, the true "goal" of research in the coming decades. 
During my PhD, I faced this issue in many respects, first observing the evidence of ge-
netic background on the individual capacity to reach successful aging and therefore, 
aiming to identify new common  markers between these diseases. 
To this end I conducted numerous association studies centered on the role of inflamma-
tory balance in determining the onset of some of the age-diseases, such as cancer, cardi-
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ovascular diseases, such as acute ischemic stroke, Thoracic Aortic Aneurysm, syndrome 
takotsubo,  myocardial infarction, Sporadic Colon Cancer, and other successful and un-
successful aging. 
In the work entitled "Genetics of longevity. Data from the studies on centenarians 
Sicilian" (Balistreri CR et al. 2012) (chapter 2) we collected our studies conducted over 
10 years on centenarians Sicilians. We evaluated the role of their individual genetic 
background on the immune response and longevity. 
In particular, we studied some genetic variants of TLR4 gene, CCR5, Cox2, 5-Lo and 
analyzed the allelic and genotypic frequencies of polymorphisms that map the genes en-
coding IFN-γ and IL-10. 
We have seen that over-expression of anti-inflammatory variants CCR5∆32, +896 G al-
lele (299Gly) TLR4, -765 C allele Cox-2 alleles -1708 G 5 and 21 C-Lo characterize 
males Sicilian centenarians. These SNPs regulating the immune- inflammatory response 
and appear to be associated with longevity. 
In addition, our results show an increase of the subjects -1082G IL10 positive, asso-
ciated with an increased production of IL-10, in males centenarians and suggest an in-
creased production of IL10 as possible biomarkers of longevity. 
In addition in Chapter 3,  we evaluated, through the Luminex technology, serum levels 
of 17 cytokines in 44 nonagenarians Sicilian and 79 control subjects (aged 30 to 50 
years) (Palmeri M. et al. 2012). We found a statistically significant increase in serum 
levels of IL6 (p=0.01), IL-12 (p=0.01) and IL13 (p=00,2) , and a decrease of IL4 
(p=00,4) in nonagenarians in comparison with controls; whereas no modifications of 
other proinflammatory cytokines and chemokines were observed.  
Our results suggest that the multiplex analysis of cytokine levels might be useful in de-
fining a successful aging profile. 
To better understand the genetic basis of complex diseases such as acute ischemic 
stroke and to outline a possible risk profile of stroke in patients with cerebrovascular 
risk factors, we evaluated, In Chapter 4, the role of SNPs of some pro-inflammatory/ 
anti-inflammatory and coagulation/fibrinolytic genes in susceptibility to acute ischemic 
stroke (Tuttolomondo A. et al 2012). 
We observed a significantly higher frequency of IL-10 1082 AA genotype in stroke pa-
tients with a significant risk trend. We also reported a higher frequency in stroke sub-
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jects with a significant risk trend of the TPA 7351-CT genotype and of IL-1RN-VNTR 
86 bp 2/2 genotype.  
Our results show, therefore, a close association between these SNPs and risk of ischem-
ic stroke. 
In a study published in "Cytokine" entitled "Myocardial infarction marker levels are in-
fluenced by prothrombin and tumor necrosis factor-a gene polymorphisms in young pa-
tients" (Vaccarino L. et al. 2012), Chapter 5,  we analyzed the effects of the genotypes 
pro-inflammatory of the TNFα and pro-thrombin (FII) on the laboratory parameters of 
young patients affected by acute myocardial infarction in comparison with a group of 
control subjects; in order to be able to use the typing of these polymorphisms in combi-
nation with the specific chemistry parameters as prognostic markers.  
The analysis of the genotype frequencies of the polymorphism -308A / G of TNF in pa-
tients and controls found an association between the genotype -308A positive (p = 
0.0048), associated with an increased production of TNFα, and risk of AMI. 
Furthermore, stratifying the data obtained with the measurement of blood parameters of 
patients affected by AMI on the basis of functional genotypes of TNF-α and FII, it indi-
cated that TNF −308A positive genotype frequencies were increased in these patients 
and that a genetically determined higher production of TNF-α is associated in young 
subjects to a more severe cardiac damage as depicted by higher levels of troponin, Crea-
tine kinase-MB Isoenzyme (mCK-MB) (p <0.0001, p <0.0001, respectively)  and a sig-
nificant increased plasma fibrinogen levels. 
Similar and probably additive effects on might have a genetically determined increased 
production of pro-thrombin even if no significant differences in genotype frequencies of 
pro-thrombin (FII) 20210G/A polymorphisms were observed in this study. 
All together these results, indicating the relationship among genetically determined 
TNFα and FII production and increased levels of tissue damage markers of AMI, sug-
gest that a complex genetic background, might be involved in susceptibility to AMI in 
young men influencing the extension and severity of the disease and thus in unsuccess-
ful aging. 
In previous studies, our group seen that a genetic background protective for cardiovas-
cular disease is an essential feature of successful aging (Candor et al., 2006a, d; Caruso 
et al., 2005). 
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Furthermore, in chapters 6  and 7 it was described another cardiovascular disease that 
characterizes aging: the Thoracic aortic aneurysm (TAA), a progressive disorder involv-
ing gradual dilation of ascending and/or descending thoracic aorta with dissection or 
rupture as complications. 
Initially, in Chapter 6,  we researched morphological phenotypes associated with the 
risk of aorta rupture and dissection in aged S-TAA individuals compared with those of 
control subjects, in order to identify a biomarker of rupture and dissection (Balistreri 
CR et al. 2014). 
Our study showed that the phenotype III characterized by elevated medial degeneration, 
plurifocal apoptosis and increased metalloproteinase-9, it was significantly correlated 
with the severity of elastic fragmentation, hypertension, and smoking, and particularly 
with advancing age. 
This might permit the assumption that phenotype III, with its typical histological ab-
normalities, is an optimal biomarker of rupture and/or dissection in aged individuals and 
is useful both for applying different surgical approaches and providing appropriate sur-
gical indications. 
In addition, in Chapter 7, we evaluated the role of five genetic variants of TGF-β 
pathways (TGF-β1 and 2 isoforms and receptors R1 and R2) and some common single 
nucleotide polymorphisms (SNPs) in the genes encoding IL-10 on susceptibility to 
TAA sporadic (Vaccarino L. et al. 2014). 
Our study included cases affected by sporadic TAA and two control groups. The most 
relevant finding obtained allows us to propose that rs900 TGF-2 SNP is associated 
with the risk of sporadic TAA.  
This might open new perspectives for the analysis of sporadic TAA susceptibility fac-
tors and prevention. 
Recently, we were interested in Takotsubo cardiomyopathy (TTC) in Chapter 8, a clin-
ical syndrome that mimics acute myocardial infarction without obstructive coronary ar-
tery disease and it characterized by transient systolic dysfunction of the apical and/or 
midial segments of the left ventricle (Novo G . et al. 2014). 
We evaluated the role of rs17098707 (L41Q) SNP  of the G-protein-coupled receptor 
kinase 5 (GRK5) on genetic susceptibility to TTC, to  favour a better understanding of 
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the pathogenesis of this peculiar syndrome,  that could allow the development of more 
appropriated preventive strategies and tailored treatment. 
Our study showed a significant difference in the frequency of the rs17098707 GRK5 
SNP between TTC patients and controls, in particular, we have found that the L41 allele 
of GRK5 is significantly increased in TTC patients (p = 0.0372) than in control group. 
So, polymorphisms of cytokines may play a role in susceptibility to this functional heart 
disease. The preliminary data presented by our research group at the recent 2nd Joint 
Meeting of Pathology and Laboratory Diagnostics (Palermo 17th-20th, September 
2014) indicate that the presence of a complex GRK5 genotype T / * - IL10 CC may be a 
predisposing factor for syndrome of Tako-Tsubo, while the presence of GRK5 AA-IL10 
A / * could have protective effects. 
Finally, in Chapter 9 in the manuscript “Genetic determined expression of pro and anti 
inflammatory mediators influence the clinical history and response to chemotherapy in 
patients with Sporadic Colorectal cancer (CRC)” (Forte GI et al. Submitted) as a first 
step, we analyzed the genetic contribute of polymorphisms known to affect the cytokine 
mRNA production to the susceptibility of sporadic colorectal cancer disease.    
No significant genetic contribute has been observed for 5 out the 6 SNPs tested. Indeed, 
a significant different allelic distribution between patients and controls has been ob-
served for the polymorphism G → C, responsible of an arginine vs. proline missense 
change (R25P) in correspondence of the codon 25 of the coding region of the TGF-
β gene (P: 0.021; Odds ratio: 0.3412; 95% C. I.: 0.1323 to 0.8800).  By this analysis, a 
weak protective role would emerge for the minor allele C in the susceptibility  to the 
disease. 
Secondly, we studied long term effect of chemotherapy on the immunological systemic 
balance of colorectal cancer patients, in particular, we analyzed the mRNA levels of 
some pro-inflammatory (IL-6, INF-γ, Cyclooxygenase (COX)-2, and anti-inflammatory 
(IL-10, TGF-β) type crucial cytokines produced by peripheral blood PMBC after at 
least 20 days from a dose administration. 
It is shown a significant increase of the IL-10 mRNA produced by PMBC, observable 
when the samples were collected within 3 months from the chemotherapy administra-
tion  as the effect of a chemotherapy treatment administration. 
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Also, it can be observed that the IL-6 mRNA levels move following an inverse behavior 
to those ones of IL-10 mRNA, although the differences are never significant. In particu-
lar, we observed lower levels of IL-6 mRNA within 3 months from the last dose of 
chemotherapy (<3MPC), probably caused by the IL-10 higher anti-inflammatory effect, 
whereas, the IL-6 levels tend to rise in the groups analyzed more than three months 
away from the chemotherapy administration (>3MPC). Instead, no relevant change is 
recorded for Cox-2, IFN-γ and TGF-β mRNAs. 
Finally, we wanted to investigate if the individual genetic background, controlled by the 
IL-10 haplotypes, could also be implicated to generate the observed higher IL-10 levels 
in response to therapy. 
It is shown, among the chemo-treated patients the GCC haplotype (high IL10 producer) 
has been observed to be significantly higher represented in patients not free of disease, 
respect to the ACC / ATA haplotypes (lower producers of IL-10) (GCC: 21 vs. ACC / 
ATA: 15; ); on the other hand, the ACC / ATA haplotypes are significantly prevalent 
among patients free from disease respect to the GCC one (39 vs.21) (P: 0.034). The ge-
netic data suggest that a greater capacity to produce IL-10 is prognostically not favora-
ble for the resolution of the disease after treatment (Odds ratio: 2,6; 95% C.I. from 1,11 
to 6.077). In addition, the genetic data justify the observation of a particularly increased 
IL-10 expression in patients receiving chemotherapy not free of disease. 
So, this data indicate that an increase genetically determined the production of IL-10 
may influence the effectiveness of the therapy. 
Moreover, as reported in the manuscript in preparation "Cytokine serum profile in a 
group of patients with colorectal carcinomas treated with the standard chemotherapy" 
(Vaccarino L. et al.) A serum profile opposite to that identified in aging successfully 
could affect the response to chemotherapy in patients with carcinoma of the colon. 
It is clear from that observed in the numerous reported case-control association studies 
that the contribution of key genes that encode cytokines such as TNF, IL-10 and TGF-
beta, involved in 
regulating the inflammatory response have a great influence of the onset of many age-
related diseases and therefore, certainly in successful aging. 
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Conclusions 
 
 
The studies reported in this thesis are put into the general framework above outlined on 
the analyses of physiopathological mechanisms implicated in age-related diseases, the 
biological events involved in aging, and genetic predispositions in longevity achieving. 
In particular, numerous case-control studies that I performed have been focused on the 
role of the inflammatory balance in determining the onset of some age-related diseases, 
as well as on aging with and without success. On this matter, the old subjects and the 
centenarians group,  most of all have been informative about the role of genes that may 
influence successful aging. 
Furthermore, the results published and summarized below confirm the importance of 
cytokines, such as central actors in the regulation of the immune response, as key me-
chanism in pathogenesis of age-related diseases and making in evidence the crucial role 
of some functionally relevant polymorphisms in cytokine genes in “inflamm-aging”. 
In future, we have a strong hope that such scientific evidence may soon be translated in-
to methods for the identification of disease risk or treatment of age-related pathologies 
in order to improve the health as well as psychological status and living conditions of 
old persons. 
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Sommario e discussione generale 
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Lo straordinario aumento dell'aspettativa di vita nei paesi più avanzati rende conto 
dell'importanza degli studi sull'invecchiamento e la longevità essendo necessario ottene-
re una rapida diffusione delle conoscenze  dei meccanismi patologici e fisiologici di in-
vecchiamento per affrontare in modo soddisfacente i problemi medici, economici e so-
ciali associati, a causa dell'aumento del numero di persone in età avanzata non autono-
me e affette da patologie invalidanti. 
I Centenari che sembrano essere “attrezzati” per raggiungere i limiti estremi della vita 
umana relativamente in buona salute, rappresentano il miglior esempio di persone in 
grado di sfuggire o rallentare la comparsa delle principali malattie legate all'età, come il 
cancro, le malattie cardiovascolari. 
L'invecchiamento è un processo di post-maturazione che, a causa di una diminuzione 
dell'efficienza dell'omeostasi ed un aumento della vulnerabilità dell'organismo, provoca 
una riduzione della risposta agli stimoli ambientali. La progressiva diminuzione delle 
capacità fisiologiche e la ridotta capacità di rispondere alle sollecitazioni portano ad una 
maggiore suscettibilità e  vulnerabilità alle malattie. Pertanto, la mortalità da qualsiasi 
causa aumenta esponenzialmente con l'invecchiamento. 
I processi di invecchiamento  coinvolgono tutte le cellule, tessuti, organi e organismi ed 
è modulata da fattori esterni. 
L'invecchiamento è accompagnato da uno stato di infiammazione cronica di basso 
grado come chiaramente dimostrato dall'aumento di 2-4 volte dei livelli sierici di 
mediatori infiammatori, come citochine e proteine della fase acuta della popolazione in 
età, che agiscono come predittori indipendenti di mortalità sulla morbidità preesistente. 
Lo stato pro-infiammatorio negli anziani, interagendo con il background genetico, 
potenzialmente innesca l'insorgenza di malattie infiammatorie legate all'età come 
l'aterosclerosi ed il cancro, (Franceschi et al., 2000a, b ; De Martinis et al).. 
Il Background genetico individuale e l'eventuale influenza di citochine anti-
infiammatorie, sembrano associati a diversi gradi di controllo della risposta 
infiammatoria e potrebbero, pertanto svolgere un ruolo determinante nell'insorgenza di 
malattie legate all'età ed al raggiungimento di età avanzata in assenza di malattie. 
Variazioni genetiche situate nelle regioni promoter di citochine pro-infiammatorie e 
regolatorie potrebbero influenzare l'inflamm-aging e la predisposizione alle malattie 
legate all'età. 
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La Sindrome Metabolica (SM) è una condizione clinica caratterizzata dalla presenza 
contemporanea di più alterazioni in un solo individuo, principalmente di origine 
metabolica, che aumenta direttamente il rischio di malattie cardiovascolari, diabete di 
tipo 2, e mortalità per tutte le cause. 
La frequenza della sindrome è età-dipendente, con un'incidenza del 44% nella 
popolazione di età compresa tra 60 e 69 anni (Ford ES. Et al.2002). 
La SM è uno stato di infiammazione cronica di basso grado come conseguenza della 
complessa interazione tra fattori genetici e ambientali. La resistenza all'insulina (IR), 
l'adiposità viscerale, la dislipidemia aterogenica, disfunzione endoteliale, suscettibilità 
genetica, pressione sanguigna elevata, stato iper coagulabilità, e lo stress cronico sono i 
diversi fattori che costituiscono la sindrome. 
Può essere la base per la comparsa di molte malattie di età. 
Questa associazione potrebbe essere dovuto al legame tra IR e infiammazione, infatti, 
gli stessi meccanismi che causano l'IR determinano sia la sintesi sia l'auto-
mantenimento della produzione di citochine pro-infiammatorie e quindi la risposta 
infiammatoria cronica e persistente che caratterizza l'inflammaging. 
Non è sorprendente che alcuni studi hanno dimostrato un'associazione tra la sindrome 
metabolica e lo sviluppo di neoplasie (Kreger BE et al 1991.), In particolare del tumore 
del colon-retto (CRC); oltre ad un aumentato rischio di diabete e malattie 
cardiovascolari (Ninomiya JK et al. 2004). 
In questo particolare contesto, la conoscenza dei polimorfismi di geni che codificano 
per citochine, è uno strumento di estrema importanza, non solo per la comprensione dei 
meccanismi alla base della patogenesi delle malattie legate all'età, ma anche per una 
futura personalizzazione dei protocolli di trattamento, il vero "obiettivo" di la ricerca nei 
prossimi decenni. 
Durante il corso di dottorato, ho affrontato la questione sotto molti aspetti, in primo 
luogo analizzando il ruolo del background genetico sulla capacità individuale di 
raggiungere l'invecchiamento di successo e, quindi, al fine di individuare nuovi 
marcatori comuni tra le  patologie che possono essere ricondotte al “common soil” della 
SM. 
A tal fine ho condotto numerosi studi di associazione incentrati sul ruolo di 
polimorfismi genici in grado di modificare l'equilibrio infiammatorio nel determinare 
146 
 
l'insorgenza di alcune delle patologie età-associate, come il cancro, le malattie 
cardiovascolari,  l'ictus ischemico acuto, aneurisma dell'aorta toracica, la sindrome 
TakoTsubo, infarto del miocardio, s cancro poradico del colon, che caratterizzano 
l'invecchiamento con o senza successo. 
 
Nell'articolo "Genetics of longevity. Data from the studies on centenarians Sicilian" 
(Balistreri CR et al. 2012) (capitolo 2) abbiamo raccolto i nostri studi condotti in 10 
anni sui centenari siciliani. Abbiamo valutato il ruolo del loro background genetico 
individuale sulla risposta immunitaria e la longevità. 
In particolare, abbiamo studiato alcune varianti genetiche dei geni TLR4, CCR5, Cox2, 
5-Lo ed analizzato le frequenze alleliche e genotipiche dei polimorfismi che mappano i 
geni che codificano IFN-γ e IL-10. 
Ciò che I nostri studi dimostrano indicano la sovraespressione di varianti anti-
infiammatori CCR5∆32, 896 G allele (299Gly) TLR4, -765 C alleli Cox-2 alleli -1708 
G 5 e 21 C-Lo che caratterizzano I centenari maschi siciliani. Questi SNP che regolano 
generalmente in senso anti-infiammatorio la risposta agli stressors  sembrano essere 
associati con la longevità. 
Inoltre, i nostri risultati mostrano un incremento dei soggetti -1082G IL10 positivi, 
associata ad un aumento della produzione di IL-10, in maschi centenari e proporre un 
aumento della produzione di IL10 come possibili biomarcatori di longevità. 
Inoltre nel capitolo 3, abbiamo valutato, attraverso la tecnologia Luminex, i livelli 
sierici di 17 citochine in 44 novantenni siciliane e 79 soggetti di controllo (di età 
compresa tra 30 a 50 anni) (Palmeri M. et al. 2012). Abbiamo trovato un aumento 
statisticamente significativo dei livelli sierici di IL6 (p = 0,01), IL-12 (p = 0,01) e IL13 
(p = 00,2), e una diminuzione di IL4 (p = 00,4) in nonagenari rispetto ai controlli; 
mentre non sono state osservate modificazioni di altre citochine proinfiammatorie e 
chemochine. 
I nostri risultati suggeriscono che l'analisi multiplex dei livelli di citochine potrebbe 
essere utile nella definizione di un profilo di invecchiamento con successo. 
Per meglio comprendere le basi genetiche di malattie complesse come l'ictus ischemico 
acuto e di delineare un profilo di rischio possibile di ictus nei pazienti con fattori di 
rischio cerebrovascolari, abbiamo valutato, nel capitolo 4, il ruolo di SNPs di alcuni 
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pro-infiammatori / anti-infiammatori e di fattori della coagulazione /fibrinolisi nella 
suscettibilità all'ictus ischemico acuto (Tuttolomondo A. et al 2012). 
Abbiamo osservato una frequenza significativamente più alta del genotipo IL-10 1082 
AA in pazienti colpiti da ictus, con un significativo trend di rischio. Abbiamo anche 
segnalato una maggiore frequenza nei soggetti con ictus con una significativa tendenza 
rischio della TPA 7351-CT genotipo e del genotipo IL-1RN VNTR-86 bp 2/2. 
I nostri risultati mostrano, quindi, una stretta associazione tra questi SNP e il rischio di 
ictus ischemico. 
In uno studio pubblicato su "Cytokine" dal titolo "Myocardial infarction marker levels 
are influenced by prothrombin and tumor necrosis factor-a gene polymorphisms in 
young patients" (Vaccarino L. et al. 2012), (capitolo 5), abbiamo analizzato gli effetti 
dei genotipi pro-infiammatoria del TNFά e pro-trombina (FII) sui parametri di 
laboratorio di  pazienti giovani affetti da infarto miocardico acuto in confronto con un 
gruppo di soggetti di controllo; per essere in grado di utilizzare la tipizzazione di questi 
polimorfismi in combinazione con i parametri di routine come marcatori prognostici. 
L'analisi delle frequenze genotipiche dei polimorfismi -308A / G del TNF in pazienti e 
controlli ha dimostrato un'associazione positiva tra il genotipo -308A (p = 0,0048), 
associato ad un aumento della produzione di TNFά., ed il rischio di AMI. Inoltre, 
stratificando i dati ottenuti con la misurazione dei parametri ematici di pazienti affetti da 
AMI sulla base di genotipi funzionali di TNF-α e FII, ha indicato che I pazienti  
TNF 308A positivi hanno una più elevata produzione dei marker di citolisi ed 
infiammazione associati  ad un più grave danno cardiaco come descritto da più elevati 
livelli di troponina, creatina chinasi-MB Isoenzima (MCK-MB) (p <0,0001, p <0.0001, 
rispettivamente) e un significativo aumento dei livelli plasmatici di fibrinogeno. 
Effetti simili e probabilmente additivi potrebbe avere un aumento geneticamente 
determinato della produzione di pro-trombina. 
Tutti insieme questi risultati, che indicano il rapporto tra l'incremento geneticamente 
determinato della produzione di TNF e  FII e l'aumento dei livelli di markers di danno 
tissutale di AMI, suggeriscono che un background genetico complesso, potrebbe essere 
coinvolto nella suscettibilità alla AMI in giovani uomini influenzando anche l'estensione 
e la gravità della malattie e condizionandone l'aspettativa di vita. 
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In studi precedenti, il nostro gruppo aveva dimostrato che un background genetico 
protettivo per la malattia cardiovascolare è una caratteristica essenziale dell' 
invecchiamento con successo (Candore et al, 2006a,d;. Caruso et al., 2005). 
Inoltre, nei capitoli 6 e 7 è stata presa in considerazione un'altra malattia 
cardiovascolare che caratterizza l'invecchiamento: l'aneurisma aortico toracico (TAA), 
una malattia  che coinvolge la progressiva dilatazione dell'aorta ascendente e / o aorta 
toracica discendente con dissezione o rottura come complicazioni. 
Inizialmente, nel Capitolo 6, abbiamo ricercato fenotipi morfologici associati con il 
rischio di rottura dell'aorta e dissezione  rispetto a quelli di soggetti di controllo, al fine 
di identificare un biomarker predittivo di queste complicanze (Balistreri CR et al. 2014) 
. 
Il nostro studio ha dimostrato che il fenotipo III caratterizzato da elevata degenerazione 
della media aortica, apoptosi plurifocale e aumento della presenza di metalloproteinasi-
9, era significativamente correlata con la gravità della frammentazione delle fibre 
elastiche, l'ipertensione e il fumo, e soprattutto con l'avanzare dell'età. 
Questo potrebbe far ipotizzare che il fenotipo III, con le sue tipiche anomalie 
istologiche, è un biomarker ottimale di rottura e/o dissezione in individui di età avanzata 
utile anche per un'appropriata scelta di  approccio chirurgico. 
Inoltre, nel capitolo 7, abbiamo valutato il ruolo di cinque varianti genetiche di percorsi 
TGF-β (TGF-β1 e 2 isoforme e recettori R1 e R2) e alcuni comuni polimorfismi a 
singolo nucleotide (SNP) nei geni codificanti IL-10 on suscettibilità al TAA sporadica 
(Vaccarino L. et al. 2014). 
Il nostro studio ha incluso casi colpiti da TAA sporadico e due gruppi di controllo. Il 
dato più rilevante ottenuto ci consente di proporre che il polimorfismo RS900 TGF-β2 
SNP è associato al rischio di sporadici TAA. 
Ciò potrebbe aprire nuove prospettive per l'analisi delle sporadiche fattori di 
suscettibilità TAA e la prevenzione. 
Recentemente, I nostri studi si sono concentrati sulla Sindrome tako-tsubo, TTC, 
(capitolo 8), una sindrome clinica che imita l'infarto miocardico acuto senza malattia 
coronarica ostruttiva e caratterizzata da una transitoria disfunzione sistolica dei 
segmenti apicali e / o Mediali del ventricolo sinistro (Novo G . et al. 2014). 
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Abbiamo valutato il ruolo di rs17098707 (L41Q) SNP del recettore G-protein-chinasi 
coupled 5 (GRK5) sulla suscettibilità genetica alla TTC, per favorire una migliore 
comprensione della patogenesi di questa sindrome particolare, che potrebbe consentire 
lo sviluppo di più appropriato strategie di prevenzione e trattamento personalizzato. 
Il nostro studio ha mostrato una differenza significativa nella frequenza della 
rs17098707 GRK5 SNP tra i pazienti TTC e controlli, in particolare, abbiamo 
dimostrato che l'allele L41 di GRK5 è significativamente aumentata nei pazienti TTC (p 
= 0,0372) rispetto al gruppo di controllo. 
Più recentemente abbiamo dimostrato che anche  polimorfismi di citochine possono 
svolgere un ruolo nella suscettibilità a questa  patologia. I dati preliminari presentati dal 
nostro gruppo di ricerca al recente 2 ° Congresso Congiunto di Patologia e Diagnostica 
di Laboratorio (Palermo 17-20, Settembre 2014) indicano che la presenza di un 
complesso GRK5 genotipo T / * - IL10 CC può essere un fattore predisponente per la 
sindrome di Tako-Tsubo, mentre la presenza di GRK5 AA-IL10 A / * potrebbe avere 
effetti protettivi. 
Infine, nel capitolo 9 nel manoscritto "Genetic determined expression of pro and anti 
inflammatory mediators influence the clinical history and response to chemotherapy in 
patients with Sporadic Colorectal cancer (CRC)" (Forte GI et al. Inviato per la 
pubblicazione)  abbiamo  analizzato il contributo di polimorfismi noti per influenzare la 
produzione di mRNA di mediatori della risposta infiammatoria alla suscettibilità della 
malattia cancro colorettale sporadica. 
Non è stato osservato un significativo contributo genetico  per 5 dei 6 SNPs testati. 
Infatti, una distribuzione allelica significativamente differente tra pazienti e controlli è 
stata osservata solo per il polimorfismo G → C, responsabile di una sostituzione 
missense arginina vs. prolina (R25P) in corrispondenza del codone 25 della regione 
codificante del gene TGF-beta  (P: 0.021; Odds ratio: 0,3412; 95% CI: 0,1323-0,8800).  
In secondo luogo, abbiamo studiato l'effetto a più lungo termine della chemioterapia 
sull'omeostasi immunologica  sistemica dei pazienti affetti da Ca del colon-retto, in 
particolare, abbiamo analizzato i livelli di mRNA di alcuni mediatori pro-infiammatori 
(IL-6, INF-gamma, ciclossigenasi (COX) -2, ed anti-infiammatori (IL-10, TGF-beta) 
prodotti da PMBC di sangue periferico dopo almeno 20 giorni dalla una 
somministrazione della dose di chemioterapico. 
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I dati ottenuti mostrano  un significativo aumento di mRNA IL-10 prodotto da PMBC, 
osservabile quando i campioni sono stati raccolti entro 3 mesi dalla somministrazione 
della chemioterapia. 
Inoltre, si può osservare che i livelli di mRNA IL-6 hanno un comportamento inverso , 
anche se le differenze non sono mai significative. In particolare, abbiamo osservato 
bassi livelli di mRNA IL-6 entro 3 mesi dall'ultima dose di chemioterapia (<3MPC), 
probabilmente causato dal superiore effetto anti-infiammatorio di IL-10, mentre i livelli 
di IL-6 tendono a risalire in  gruppi analizzati più di tre mesi dopo la somministrazione 
della chemioterapia (> 3MPC). Invece, nessun cambiamento rilevante è stao registrato 
per I messaggeri di Cox-2,IFN-gamma e TGF-beta. 
Infine, abbiamo voluto verificare se il background genetico individuale, controllato 
dagli aplotipi IL-10  potrebbe anche essere implicato nella modulazione della risposta 
alla terapia adiuvante. 
È stato dimostrato, tra i pazienti trattati con chemioterapia l'aplotipo GCC (alto 
produttore IL10) è significativamente più  rappresentato in pazienti non liberi da 
malattia, rispetto agli aplotipi  ACC /  ATA (bassi produttori di IL-10) (GCC : 21 vs 
ACC / ATA: 15;); d'altra parte, gli aplotipi ACC / ATA sono significativamente 
prevalenti tra i pazienti liberi da malattia rispetto a quello GCC (39 vs.21) (P: 0.034). I 
dati genetici suggeriscono che una maggiore capacità di produrre IL-10 non è 
prognosticamente favorevole per la risoluzione della malattia dopo il trattamento (OR: 
2,6; 95% CI da 1,11 a 6,077). Inoltre, i dati genetici giustificano l'osservazione di un 
particolare aumentata espressione di IL-10 in pazienti sottoposti a chemioterapia non 
liberi da malattia. 
Quindi, questi dati indicano che un aumento geneticamente determinata la produzione 
di IL-10 può modulare l'efficacia della terapia. 
Infine, come riportato nel manoscritto in preparazione "Cytokine serum profile in a 
group of patients with colorectal carcinomas treated with the standard chemotherapy" 
(Vaccarino L. et al.) Un profilo sierico opposto a quello individuato nell'invecchiamento 
con successo potrebbe influenzare la risposta chemioterapia in pazienti con carcinoma 
del colon. 
Appare quindi chiaro che nel loro insieme gli studi di associazione caso-controllo 
indicano che geni chiave che codificano per citochine come TNF, IL-10 e TGF-beta, 
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coinvolti nella regolazione della risposta infiammatoria possono avere una grande 
influenza sull'insorgenza di molte malattie legate all'età e quindi, sull'invecchiamento 
con successo. 
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Conclusioni 
 
 
Gli studi riportati in questa tesi rientrano nel quadro generale sopra delineato delle 
analisi dei meccanismi fisiopatologici implicati in malattie legate all'età, gli eventi 
biologici coinvolti nell'invecchiamento, e la predisposizione genetica alla longevità. 
In particolare, numerosi studi caso-controllo  si sono concentrati sul ruolo della 
regolazione della risposta  infiammatoria nel determinare l'insorgenza di alcune malattie 
legate all'età, nonché sull'invecchiamento con e senza successo. A questo proposito, i 
soggetti anziani e il gruppo centenari, soprattutto sono stati informativi sul ruolo dei 
geni che possono influenzare l'invecchiamento con successo. 
Inoltre, i risultati pubblicati  confermano l'importanza delle citochine, come attori 
centrali nella regolazione della risposta immunitaria, come meccanismo chiave nella 
patogenesi delle malattie legate all'invecchiamento ed evidenziano il ruolo cruciale di 
alcuni polimorfismi di geni funzionalmente rilevanti per l'"inflamm-aging". 
In futuro, abbiamo una forte speranza che tali evidenze scientifiche possano  tradursi in 
metodi per l'identificazione del rischio o il trattamento di patologie legate 
all'invecchiamento, al fine di migliorare le condizioni di vita e lo stato di salute delle 
persone anziane. 
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